GB2155470A - Substituted peptide compounds - Google Patents

Substituted peptide compounds Download PDF

Info

Publication number
GB2155470A
GB2155470A GB08505628A GB8505628A GB2155470A GB 2155470 A GB2155470 A GB 2155470A GB 08505628 A GB08505628 A GB 08505628A GB 8505628 A GB8505628 A GB 8505628A GB 2155470 A GB2155470 A GB 2155470A
Authority
GB
United Kingdom
Prior art keywords
proline
oxo
mmole
benzoylamino
ester
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GB08505628A
Other versions
GB2155470B (en
GB8505628D0 (en
Inventor
Sesha I Natarajan
Eric M Gordon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ER Squibb and Sons LLC
Original Assignee
ER Squibb and Sons LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Publication of GB2155470B publication Critical patent/GB2155470B/en
Application filed by ER Squibb and Sons LLC filed Critical ER Squibb and Sons LLC
Priority to GB08505628A priority Critical patent/GB2155470A/en
Publication of GB8505628D0 publication Critical patent/GB8505628D0/en
Publication of GB2155470A publication Critical patent/GB2155470A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06086Dipeptides with the first amino acid being basic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Abstract

Intermediate amides of the formula R<2>-CO-NH-CH(R<3>)-CO-CH2Cl are claimed. These compounds are useful as intermediates for substituted peptide compounds of the formula <IMAGE> which are hypotensive agents and also useful as analgesics and are the subject of the patent application 83. 18492.

Description

SPECIFICATION Substituted peptide compounds This invention is directed to substituted peptide compounds of formula land salts thereof (I)
Xis an amino or imino acid of the formula
R7 is hydrogen, lower alkyl, halogen, keto, hydroxy,
lower alkyl, azido, amino,
a 1- or 2-naphthyl of the formula
(CH2)rn-cycloalkyl,
-O-lower alkyl,
a 1-or 2-naphthyloxy of the formula
-S-lower alkyl,
or a 1- or 2-naphthylthio of the formula
R8 is keto, halogen,
-O-lower alkyl, a 1- or 2-naphthyloxy of the formula
-S-lower alkyl,
our a 1- or 2-naphthylthio of the formula
Rg is keto or
R10 is halogen or -Y-R16.
R11, R'11, and R'l2 are independently selected from hydrogen and lower alkyl or R'11, R12 and R'l2 are hydrogen and R11 is
Rl3 is hydrogen, lower alkyl of 1 to 4 carbons, lower alkoxy of 1 to 4 carbons, lower alkylthio of 1 to 4 carbons, chloro, bromo, fluoro, trifluoromethyl, hydroxy, phenyl, phenoxy, phenylthio, or phenylmethyl.
Rl4 is hydrogen, lower alkyl of 1 to 4 carbons, lower alkoxy of 1 to 4 carbons, lower alkylthio of 1 to 4 carbons, chloro, bromo, fluoro, trifluoromethyl, or hydroxy.
m is zero, one, two, three, or four.
p is one, two or three provided that p is more than one only if Rl3 or R14 is hydrogen, methyl, methoxy, chloro, or fluoro.
R15 is hydrogen or lower alkyl of 1 to 4 carbons. Y is oxygen or sulfur.
R16 is lower alkyl of 1 to 4 carbons,
or the R16 groups join to complete an unsubstituted 5- or 6-membered ring or said ring in which one or more of the carbons has a lower alkyl of 1 to 4 carbons or a di (lower alkyl of 1 to 4 carbons) substituent.
R4 is hydrogen, lower alkyl,
-(CH2)m,-cycloalkyl,
F5 is hydrogen, lower alkyl,
-(CH2)x-NH2, -(CH2)x-SH, -(CH2)x-S-lower alkyl,
r is an integer from 1 to 4.
R19 is lower alkyl, benzyl, or phenethyl.
R20 is hydrogen, lower alkyl, benzyl or phenethyl.
R is hydrogen, lower alkyl, cycloalkyl,
-(CH2)2-NH2, -(CH2)3-NH2 , -(CH2)4-NH2, -(CH2)2-OH, -(CH2)3-OH, -(CH2)4-OH, -(C, H2) 2-SH, -(CH2)3-SH, or -(CH2)4-SH.
R1 is hydrogen, lower alkyl, halo substituted lower alkyl,
-(CH2)r-NH2, -(CH2)r-SH, -(CH2)r-OH, -(CH2)r-S-lower alkyl,
provided that R1 is hydrogen only if R is other than hydrogen.
R2 is
R3 is hydrogen, lower alkyl,
halo substituted lower alkyl, -(CH2)m-cycloalkyl,
(CH2)rNH2, (CH2)rSH, -(CH2)r-S-lower alkyl,
wherein m, R14, p and rare as defined above.
Rg is hydrogen, lower alkyl, benzyl, benzhydryl,
R17 is hydrogen, lower alkyl, cycloalkyl, or phenyl.
R18 is hydrogen, lower alkyl, lower alkoxy, or phenyl or R17 and R18 taken together are -(CH2)2-, -(CH2)3-, -CH=CH-, or
F21 and F22 are independently selected from hydrogen and lower alkyl.
R23 is lower alkyl.
This invention in its broadest aspects relates to the substituted peptide compounds of formula I above, to compositions and the method of using such compounds as pharmaceutical agents, and to intermediates useful in preparing these compounds.
The term lower alkyl used in defining various symbols refers to straight or branched chain radicals having up to seven carbons. The preferred lower alkyl groups are up to four carbons with methyl and ethyl most preferred. Similarly the terms lower alkoxy and lower alkylthio refer to such lower alkyl groups attached to an oxygen or sulfur.
The term cycloalkyl refers to saturated rings of 3 to 7 carbon atoms with cyclopentyl and cyclohexyl being most preferred.
The term halogen refers to chloro, bromo and fluoro.
The term halo substituted lower alkyl refers to such lower alkyl groups described above in which one or more hydrogens have been replaced by chloro, bromo orfluoro groups such as trifluoromethyl, which is preferred, pentafluoroethyl, 2,2,2-trichloroethyl, chloromethyl, bromomethyl, etc.
The symbols
and
represent that the alkylene bridge is attached to an available carbon atom. The compounds of formula I wherein R is hydrogen can be prepared by converting a carboxymethyl peptide ester of the formula (II)
to its acid chloride and then reacting with an oxazolone of the formula (III)
wherein R40 and Rg (in the definition of X) are protecting groups such as, for example, wherein R40 is benzyloxycarbonyl and R6 is benzyl. Removal of the R40 and R6 protecting group, for example, by hydrogenation yields the products of formula I wherein Fe is hydrogen.
The carboxymethyl peptide ester of formula II is prepared by reacting the peptide ester of the formula (IV)
with tert-butyl bromoacetate and then introducing the R40 protecting group, for example, by treating with benzyl chloroformate.
The compounds of formula I can also be prepared by reacting a ketone of the formula (V)
wherein halo is Cl or Br with the peptide ester of the formula (VI)
in the presence of base such as sodium bicarbonate followed by removal of the R6 ester group.
The ketone intermediate of formula V can be prepared by treating a ketone of the formula (Vll)
wherein R40 is a protecting group such as benzyloxycarbonyl with hydrogen bromide and acetic acid followed by reaction with the acid halide of the formula (VIII)
in the presence of base such as sodium bicarbonate.
The compounds of formula I can also be prepared by reacting an aminoketone of the formula (IX)
particularly the hydrochloride salt thereof with the haloacetyl amino or imino acid ester of the formula (X)
wherein Rg in the definition of X is an easily removable ester protecting group and halo is Cl or Br.
The compounds of formula I can also be prepared by coupling an aminoketone carboxylic acid of the formula (Xl)
with the amino or imino acid ester of the formula (XII) HX in the presence of a coupling agent such as dicyclohexylcarbodiimide wherein R6 in the definition of X is an easily removable protecting group. Removal of the Rg protecting group yields the products of formula I wherein R6 is hydrogen.
The aminoketone of formula IX can be prepared by converting the carboxyalkylamine of the formula (XIII)
wherein R40 is a protecting group such as benzyloxycarbonyl, to its acid chloride and then reacting with an oxazolone of formula Ill to yield (XIV)
Removal of the R40 protecting group such as by hydrogenation yields the reactant of formula IX.
The aminoketone of formula IX wherein R is other than hydrogen can also be prepared by reacting the ketone of formula V with a substituted amine of the formula (XV) F-NH2 The aminoketone carboxylic acid of formula Xl can be prepared by reacting the aminoketone of formula IX with a haloacetic acid ester of the formula (XVI)
wherein Prot is an easily removable ester producing group such as t-butyl to yield the ester (XVII)
Removal of the ester protecting group gives the reactant of formula Xl.
In the above reactions if any or all of R, R1, F3 and F5 are
-(CHZ)-OHI 9r
then the hydroxyl, amino, imidazolyl, mercaptan or guanidinyl function should be protected during the reaction. Suitable protecting groups include benzyloxycarbonyl, t-butoxycarbonyl, benzyl, benzhydryl, trityl, etc., and nitro in the case of guanidinyl. The protecting group is removed by hydrogenation, treatment with acid, or other known methods following completion of the reaction.
The ester products of formula I wherein Rg is lower alkyl, benzyl or benzhydryl can be chemically treated such as with sodium hydroxide in aqueous dioxane or with trimethylsilylbromide to yield the products of formula I wherein F6 is hydrogen. The benzyl and benzhydryl esters can also be hydrogenated, for example, by treating with hydrogen in the presence of a palladium on carbon catalyst.
The ester products of formula I wherein Rg is
may be obtained by employing the peptide of formula IV or VI or the haloacetyl amino or imino acid ester of formula X in the above reactions with such ester group already in place. Such ester reactants can be prepared by treating the peptide of formula IV or VI or the haloacetyl amino or imino acid ester of formula X wherein Rg is hydrogen with an acid chloride such as
so as to protect the N-atom. The protected compound is then reacted in the presence of a base with a compound of the formula (XVIII)
wherein Lisa leaving group such as chlorine, bromine, tolylsulfonyl, etc., followed by removal of the N-protecting group such as by treatment with acid or hydrogenation.
The ester products of formula I wherein F6 is
can also be obtained by treating the product of formula I wherein Rg is hydrogen with a molar excess of the compound of formula XVIII.
The ester products of formula I wherein Re is
can be prepared by treating the product of formula I wherein R6 is hydrogen with a molar excess of the compound of the formula (XIX)
The ester products of formula I wherein F6 is -CH-(CH-OH)2 or
can be prepared by coupling the product of formula I wherein Rg is hydrogen with a molar excess of the compound of the formula (XX)
or the formula (XXI)
in the presence of a coupling agent such as dicyclohexylcarbodiimide followed by removal of the hydroxyl protecting groups.
The esters of formula I wherein F6 is lower alkyl can be obtained from the carboxylic acid compounds, i.e., wherein R6 is hydrogen, by conventional esterification procedures, e.g., treatment with an alkyl halide of the formula R6-halo or an alcohol ef the formula R6-OH.
The peptide esters of formulas IV and Vi may be obtained by coupling the hydrochloride salt of the amino or imino acid ester of formula XII wherein F6 is, for example, benzyl with the N-protected amino acid of the formula (XXII)
wherein Prot is a protecting group such as
Preferably, this reaction is performed in the presence of a coupling agent such as dicyclohexylcarbodiimide.
Removal of the N-protecting group, for example, by treatment with trifluoroacetic acid yields the peptide esters of formulas IV and VI.
The haloacetyl amino or imino acid ester of formula X can be prepared by reacting the amino or imino acid ester of formula Xli with a haloacetylhalide of the formula (XXIII)
The products of formula I wherein R7 is amino may be obtained by reducing the corresponding products of formula I wherein R7 is azido.
Preferred compounds of this invention with respect to the peptide part of the structure of formula I are those wherein: R is hydrogen, straight or branched chain lower alkyl of 1 to 4 carbons, or phenyl.
R1 is hydrogen, straight or branched chain lower alkyl of 1 to 4 carbons, -CF3, -(CH2)r-NH2 wherein r is an integerfrom 1 to 4,
-(CH2)2-S-CH3, !
provided that R1 is hydrogen only if R is other than hydrogen.
F4 is hydrogen, cyclohexyl or phenyl.
R5 is hydrogen, straight or branched chain lower alkyl of 1 to 4 carbons, -CH2OH,
- (cH2) 4-NH2 , -CH2-SH, - (CH2)2-S-CH3,
R8 is hydrogen, straight or branched chain lower alkyl of 1 to 4 carbons, alkali metal salt,
R23 is straight or branched chain lower alkyl of 1 to 4 carbons, especially -C(CH3)3.
R17 is hydrogen, straight or branched chain lower alkyl of 1 to 4 carbons, or cyclohexyl.
R18 is straight or branched chain lower alkyl of 1 to 4 carbons or phenyl.
R is straight or branched chain lower alkyl of 1 to 4 carbons, especially -C(CH3)3.
R7 is hydrogen.
R7 is hydroxy.
R7 is straight or branched chain lower alkyl of 1 to 4 carbons or cyclohexyl.
R7 is amino.
R7 is -O-lower alkyl wherein lower alkyl is straight or branched chain of 1 to 4 carbons.
R7 is
wherein m is zero, one or two and R13 is hydrogen, methyl, methoxy, methylthio, chloro, bromo, fluoro, or hydroxy.
R7 is
1-naphthyloxy or 2-naphthyloxy wherein m is zero, one, or two and R13 is hydrogen, methyl, methoxy, methylthio, chloro, bromo, fluoro, or hydroxy.
R7 is -S-lower alkyl wherein lower alkyl is straight or branched chain of 1 to 4 carbons.
R7 is
1-naphthylthio, or 2-naphthylthio wherein m is zero, one, or two and R13 is hydrogen, methyl, methoxy, methylthio, chloro, bromo, fluoro, or hydroxy.
F8 is -O-lower alkyl wherein lower alkyl is straight or branched chain of 1 to 4 carbons. R8 is
wherein m is zero, one, or two and R13 is hydrogen, methyl, methoxy, methylthio, chloro, bromo, fluoro, or hydroxy.
F8 is -S-lower alkyl wherein lower alkyl is straight or branched chain of 1 to 4 carbons. F8is
wherein m is zero, one or two and R13 is hydrogen, methyl, methoxy, methylthio, chloro, bromo, fluoro or hydroxy.
Rg is phenyl, 2-hydroxyphenyl, or 4-hydroxyphenyl.
R10 are both fluoro or chloro.
R1o are both-Y-R16 wherein Y is O or S, R16 is straight or branched chain lower alkyl of 1 to 4 carbons or the R16 groups join to complete an unsubstituted 5- or 6-membered ring or said ring in which one or more of the available carbons has a methyl or dimethyl substituent.
R11, R'11, R12 and R'a2 are all hydrogen, or R11 is phenyl, 2-hydroxyphenyl, or 4-hydroxyphenyl and R'1l, R12- and R'12 are hydrogen.
Most preferred compounds of this invention with respect to the peptide part of the structure of formula I are those wherein: Xis-
R is hydrogen or methyl.
R1 is hydrogen, methyl, or -(CH2)4NH2, especially methyl, provided that R1 is hydrogen only if R is other than hydrogen.
R6 is hydrogen, straight or branched chain lower alkyl of 1 to 4 carbons, or an alkali metal salt.
R4 is cyclohexyl or phenyl.
R7 is hydrogen, cyclohexyl, lower alkoxy of 1 to 4 carbons,
wherein m is zero, one, or two and R13 is hydrogen, methyl, methoxy, methylthio, Cl, Br, F, or hydroxy, especially preferred wherein R7 is hydrogen.
t is two or three, especially where t is two.
Preferred compounds of this invention with respect to the keto portion of the structure of formula I are those wherein: Rains
wherein m is zero, one, or two and Ra4 is hydrogen, methyl, methoxy, methylthio, Cl, Br, F, or hydroxy, especially phenyl.
R3 is straight or branched chain lower alkyl of 1 to 4 carbons, - -(CH2),-NH2,
wherein m is zero, one, or two, R,4 is hydrogen, methyl, methoxy, methylthio, Cl, Br, F, or hydroxy, and r is an integer from 1 to 4, especially benzyl.
The compounds of formula I wherein Rg is hydrogen form salts with a variety of inorganic or organic bases. The nontoxic, pharmaceutically acceptable salts are preferred, although other salts are also useful in isolating or purifying the product. Such pharmaceutically acceptable salts include metal salts such as sodium, potassium or lithium, alkaline earth metal salts such as calcium or magnesium, and salts derived from amino acids such as arginine, lysine, etc. The salts are obtained by reacting the acid form of the compound with an equivalent of the base supplying the desired ion in a medium in which the salt precipitates or in aqueous medium and then lyophilizing.
Similarly, the compounds of formula I, especially wherein R6 is an ester group, form salts with a variety of inorganic and organic acids. Again, the non-toxic pharmaceutically acceptable salts are preferred, although other salts are also useful in isolating or purifying the product. Such pharmaceutically acceptable salts include those formed with hydrochloric acid, methanesulfonic acid, sulfuric acid, maleic acid, etc. The salts are obtained by reacting the product with an equivalent amount of the acid in a medium in which the salt precipitates.
As shown above, the peptide portion of the molecule of the products of formula I represented by
is in the L-configuration. An asymmetric center is also present in the keto portion of the molecule when F3 is other than hydrogen. Thus, the compounds of formula I can exist in diastereoisomeric forms or in mixtures thereof. The above described processes can utilize racemates, enantiomers or diastereomers as starting materials. When diastereomeric products are prepared, they can be separated by conventional chromatographic or fractional crystallization methods.
The products of formula I wherein the imino acid ring is monosubstituted give rise to cistrans isomerism.
The configuration of the final product will depend upon the configuration of the R7, R8 and Rg substituent in the starting material of formula XII.
The compounds of formula I, and the pharmaceutically acceptable salts thereof, are hypotensive agents.
They inhibit the conversion of the decapeptide angiotensin I to angiotensin II and, therefore, are useful in reducing or relieving angiotensin related hypertension. The action of the enzyme renin on angiotensinogen, a pseudoglubulin in blood, produces angiotensin I. Angiotensin I is converted by angiotensin converting enzyme (ACE) to angiotensin II. The latter is an active pressor substance which has been implicated as the causative agent in several forms of hypertension in various mammalian species, e.g., humans. The compounds of this invention intervene in the ang iotensinogen (renin) angiotensin I -, angiotensin II sequence by inhibiting angiotensin converting enzyme and reducing or eliminating the formation of the pressor substance angiotensin II.Thus by the administration of a composition containing one (or a combination) of the compounds of this invention, angiotensin dependent hypertension in a species of mammal (e.g., humans) suffering therefrom is alleviated. A single dose, or preferably two to four divided daily doses, provided on a basis of about 0.1 to 100 mg., preferably about 1 to 50 mg., per kg. of body weight per day is appropriate to reduce blood pressure. The substance is preferably administered orally, but parenteral routes such as the subcutaneous, intramuscular, intravenous or intraperitoneal routes can also be employed.
The compounds of this invention can also be formulated in combination with a diuretic for the treatment of hypertension. A combination product comprising a compound of this invention and a diuretic can be administered in an effective amount which comprises a total daily dosage of about 30 to 600 mg., preferably about 30 to 330 mg. of a compound of this invention, and about 15 to 300 mg., preferably about 15 to 200 mg.
of the diuretic, to a mammalian species in need thereof. Exemplary of the diuretics contemplated for use in combination with a compound of this invention are the thiazide diuretics, e.g., chlorothiazide, hydrochlorothiazide, flumethiazide, hydroflumethiazide, bendroflumethiazide, methyclothiazide, trichloromethiazide, polythiazide or benzthiazide as well as ethacrynic acid, ticrynafen, chlorthalidone, furosemide, musolimine, bumetanide, triamterene, amiloride and spironolactone and salts of such compounds.
The compounds of formula I can be formulated for use in the reduction of blood pressure in compositions such as tablets, capsules or elixirs for oral administration, or in sterile solutions or suspensions for parenteral administration. About 10 to 500 mg. of a compound of formula I is compounded with physiologically acceptable vehicle, carrier, excipient, binder, preservative, stabilizer, flavor, etc., in a unit dosage form as cailed for by accepted pharmaceutical practice. The amount of active substance in these compositions or preparations is such that a suitable dosage in the range indicated is obtained.
The compounds of formula I wherein X is
also possess enkephalinase inhibition activity and are useful as analgesic agents. Thus, by the administration of a composition containing one our a combination of such compounds of formula I our a pharmaceutically acceptable salt thereof, pain is alleviated in the mammalian host. A single dose, or preferably two to four divided daily doses, provided on a basis of about 0.1 to about 100 mg. per kilogram of body weight per day, preferably about 1 to about 50 mg. per kilogram per day, produces the desired analgesic activity. The composition is preferably administered orally but parenteral routes such as subcutaneous can also be employed.
The following examples are illustrative of the invention. Temperatures are given in degrees centigrade.
LH-20 refers to a Sephadex chromatography gel commercially available from Pharmacia Fine Chemicals.
EXAMPLE 1 1-[N-13-rSenzoylamino)-2-oxo-4-phenylbutyll-L-alanyll-L-proline, monohydrochoride a! L-Alanyl-L-proline, phenylmethyl ester, p-toluenesulfonic acid salt N-[(1 1 -Dimethylethoxy)carbonyl]-L-alanine (310.7 g.), L-proline, phenylmethyl ester, hydrochloride (396.2 g.), dicyclohexylcarbodiimide (338.6 g.), hydroxybenzotriazole hydrate (251.5 g.), diisopropyiethylamine (285.7 ml.), and tetrahydrofuran (5 liters) are combined at 0 (dicyclohexylcarbodiimide is added last) and stirred at room temperature overnight. The reaction mixture is filtered and concentrated. The residue is dissolved in 41. of ethyl acetate and washed with 5% sodium bicarbonate (2 x 2 1.), 5% potassium bisulfate 2 x 2 1.) and water.The ethyl acetate layer is dried (MgSO4) and concentrated. The residue is dissolved in 3 1. of diethyl ether and left at 0" overnight. The mixture is filtered and the filtrate concentrated to yield 620 g.
of crude N-[(1 ,1 -dimethylethoxy)carbonyl]-L-alanyl-L-proline, phenylmethyl ester.
N-[(1,1-Dimethylethoxy)carbonyl]-L-alanyl-L-prnline, phenylmethyl ester (275 g.) is chilled in an ice bath and treated with 500 ml. of cold trifluoroacetic acid (freshly distilled) under argon and stirred at room temperature for one hour. The mixture is concentrated in vacuo and azeotroped twice with toluene. The crude trifluoroacetic acid salt, an oil, is dissolved in 500 ml. of ether and treated slowly with stirring with a solution of p-toluenesulfonic acid hydrate (1 equivalent) dissolved in 6 1. of ether. The resultant precipitate is collected by filtration. The solid is dissolved in 11. of methanol and treated with 4 1. of ether and chilled. The resuitant precipitate is collected and dried to give 300 g. of L-alanyl-L-proline, phenylmethyl ester, p-toluenesulfonic acid salt; m.p. 156-158".
b) 1-[N-[2-(1,1-Dimethylethoxy)-2-oxoethyl]-N-[(phenylmethoxy)carbonyl]-L-alanyl]-L-proline, phenylmethyl ester A mixture of L-alanyl-L-proline, phenylmethyl ester, p-toluenesulfonic acid salt (32.16 g., 72 mmole), tert-butyl bromoacetate (14.2 g., 72 mmole), triethylamine (20.1 ml., 144 mmole), and tetrahydrofuran (290 ml.) are stirred at room temperature for 72 hours. Benzyl chloroformate (12.4 ml., 87.8 mmole) and triethylamine (12.5 ml., 87.8 mole) are added and the mixture stirred overnight. The reaction product is evaporated, and partitioned between water and ethyl acetate. The ethyl acetate solubles are washed with dilute hydrochloric acid and then water.The ethyl acetate solution is then evaporated and chromatographed over silica gel (mesh 230 - 400) using the solvent system ethyl acetate/hexane (1 :1) (10 psi pressure) to give 19.5 g. of 1-[N-[2-(1,1-dimethylethylethoxy)-2-oxoethyl]-N-[(phenylmethoxy)carbonyl]-L-alanyl]-L-proline, phenylmethyl ester.
c) I-[N-lCarboxymethyl)-N-[l,henylmethoxyJ carbonyl]-L-alanyl]-Lornllne, phenylmethyl ester 1 -[N-[2-(1 ,1 -Dimethylethoxy)-2-oxoethyl]-N-[(phenylmethoxy) carbonyl]-L-alanyi]-L-proline, phenylmethyl ester (18 g., 34.3 mmole) is dissolved in trifluoroacetic acid (50 ml.) and let stand at room temperature for 1.5 hours. The mixture is evaporated and filtered through a small column of silica gel (200 g.) using the solvent mixture chloroformlmethanol/acetic acid (9.6:0.2:0.2) to give 11.4 g. of 1-[N-(carboxymethyl)-N-[ (pheny [methoxy)carbonyl]-L-alanyl]-L-proline, phenylmethyl ester.
d) 1-[N-[3-(Benzoylamino)-2-oxo-4-phenylbutyl]-N-[(phenylmethoxy)carbonyl]-L-alanyl]-L-proline, pheny Imethyl ester 1-[N-(carboxymethyl)-N-[(phenylmethoxy) carbonyl]-L-alanylj-L-proline, phenylmethyl ester (7.0 g., 15.0 mmole) is dissolved in dry tetrahydrofuran (50 ml.) and cooled in an ice bath, oxalyl chloride (1.57 ml., 18 mmole) is added followed by 4 drops of dimethylformamide. After 15 minutes, the reaction mixture is stirred at room temperature for an additional period of one hour. The mixture is evaporated, redissolved in tetrahydrofuran (30 ml.) and the solution is cooled in an ice bath.The solution is added dropwise over a period of 5 minutes to an ice-cold solution of 2-phenyl-4-(phenyl-methyl)-5(4H)-oxazolone (3.96 g., 15.75 mmole) in tetrahydrofuran (24 ml.). Triethylamine (2.5 ml., 17.1 mmole) is added and the reaction mixture is stirred at room temperature overnight. The mixture is filtered to remove triethylamine hydrochloride salt and the filtered tetrahydrofuran solution is evaporated and redissolved in pyridine (16 ml.). 4-Dimethylamino pyridine (50 mg.) is added and the solution is stirred at room temperature for 3 hours. Glacial acetic acid (16 ml.) is added and the reaction mixture is heated at 100" for 45 minutes.The reaction mixture is then cooled, evaporated under vacuum, dissolved in ethyl acetate and extracted with aqueous sodium bicarbonate and dilute hydrochloric acid. The ethyl acetate extract after evaporation is chromatographed over silica gel (230-400 mesh) using the solvent system ethyl acetate/benzene (4:6) to obtain 4.9 g. of 1-[N-[3 (benzoylamino)-2-oxo-4-phenylbutyl]-N-[(phenylmethoxy)carbonyl]-L-alanyl]-L-proline, phenylmethyl ester.
Anal. calc'd. for C40H41N307 ' 0.42 H2O: C,70.31; N,6.15; H,6.17 Found: C, 70.31; N, 6.13; H, 6.08.
e) 1-[N-[3-(Benzoylamino)-2-oxo-4-phenylbutyl]-L-alanyl]-L-proline, monohydrochloride 1 -[N-[3-(Benzoylamino)-2-oxo-4-phenylbutylj-N-[(phenylmethoxy)carbonyl]-L-alanylj-L-proline, phneylmethyl ester (1.0 g.) is dissolved in absolute ethanol (30 ml.) and 1 N hydrochloric acid (2.25 ml.).
Palladium-carbon catalyst (10%, 200 mg.) is added and the solution is stirred under an atmosphere of hydrogen overnight. The catalyst is filtered off and the solution is evaporated. The crude product (700 mg.) is combined with 300 mg. of crude product from a previous small scale reaction and passed through a column of LH-20 (1 inch x 15 inch) in methanol. The fractions containing the desired product are pooled, evaporated, dissolved in water and filtered. The clear aqueous solution is lyophilized to give 800 mg. of 1-[N-[3- (benzoylamino)-2-oxo-4-phenylbutyl]-L-alanyl]-L-proline, monohydrochloride; [)2o5 = -59.6 (c=1.4, methanol); m.p. 98-130 (dec.).
Tic (silica gel, n-butanol/acetic acid/water, 4:1:1) Rf = 0.44.
Anal. calc'd. for C25H30N305CI . 0.75 H2O: C, 59.88; H, 6.33; N, 8.38; Cl, 7.07 Found: C, 59.82; H, 6.30; N, 8.42; Cl, 6.85.
EXAMPLE 2 1-[N-7-Amino-3-rBenzoylamino)-2-oxoheptylJ-L-alanyl7-L-proline, dihydrochloride a) N2-Benzoyl-N6-[phenylmethoxy)carbonyl]-L-lysine To an ice-cold solution of N6-[(phenylmethoxy)carbonyl]-L-lysine (10.09 g., 36 mmole) in aqueous sodium hydroxide (1 N, 26 ml.) is added benzoyl chloride (5 ml., 43.2 mmole) and aqueous sodium hydroxide (4N, 10.8 ml.) simultaneously in 5 portions over a period of 30 minutes. The ice bath is removed and stirring is continued for an additional 1.5 hours at room temperature. The reaction mixture is then extracted with ethyl acetate (discarded), the aqueous mother liquor is acidified with dilute hydrochloric acid and extracted with ethyl acetate.The ethyl acetate extract is concentrated and the residue crystallized from ethyl acetatehexane to give 12.9 g. of N2-benzoyl-N6-[(phenylmethoxy)carbcnylj-L-lysine; m.p. 110-112' (109').
b) 2-Phenyl-4-[4-[[(phenylmethoxy)carbonyl]amino]-butyl]-5(4H)-oxazolone N2-Benzoyl-N8-[(phenylmethoxy)carbonylj-L-lysine (11.53 g., 30 mmole) is dissolved in tetrahydrofuran (55 ml.) and stirred in an ice-bath. To this reaction mixture a solution of dicyclohexylcarbodiimide (6.8 g., 33 mmole) in tetrahydrofuran is added dropwise over a period of 15 minutes. The ice-bath is removed after an hour and stirring is continued at room temperature for an additional 18 hours. Dicyclohexylurea is filtered off and the tetrahydrofuran is concentrated in vacuo. The residue is crystallized from ethyl acetate-hexane to give 9.4 g. of 2-phenyl-4-[4-[[(phenylmethoxy) carbonyl]amino]butyl]-5(4H)-oxazolone; m.p. 72-73" (68 ).
c) 1-[N-[3-(Benzoylamino)-7-[[(phenylmethoxy)-carbonyl]amino]-2-oxoheptyl]-N-[(phenylmethoxy)- carbonyl]-L-alanyl]-L-proline, phenylmethyl ester 1-[N-(Carboxymethyl)-N-[(phenylmethoxy)-carbonyl]-L-alanyl]-L-proline, phenylmethyl ester (2.82 g., 6 mmole), from Example 1 (c), is dissolved in tetrahydrofuran (20 ml.) and the solution is stirred in an ice-bath.
Oxalyl chloride (0.63 ml., 7.2 mmole) is added followed by four drops of dimethylformamide. After stirring this reaction mixture in an ice-bath for 20 minutes, it is then stirred at ambient temperature for an additional hour. The solvents are removed in vacuo and the residue is redissolved in tetrahydrofuran (10 ml.) and cooled in an ice-bath. To this cold stirring solution is added a cold solution 2-phenyl-4-[4 [[(phenylmethoxy)carbonyl]amino]butyl]-5(4H)-oxazolone (2.2 g., 6 mmole) in tetrahydrofuran (14 ml.), followed by triethylamine (0.85 ml., 6 mmole). The ice-bath is removed and the reaction mixture is stirred at ambient temperature overnight. The precipitated triethylamine-hydrochloride is removed by filtration and the mother liquor is concentrated in vacuo.It is then redissolved in pyridine (6 ml.), 4-dimethylamino pyridine (30 mg.) is added, and the solution is stirred at room temperature for 3 hours. Acetic acid (6 ml.) is added and the reaction mixture is heated at 105 for 45 minutes. it is then evaporated, taken up into ethyl acetate, and washed with water, dilute hydrochloric acid, and aqueous sodium bicarbonate. After evaporation of the solvent, the crude product (3.8 g.) is chromatographed (silica gel, 230 g.) using ethyl acetate-hexane (4:3) followed by ethyl acetate-hexane (2:1) for elution to give 1.8 g. of 1-[N-[3 (benzoylamino)-7-[[(phenylmethoxy)-carbonyl]amino]-2-oxoheptyl]-N-[(phenylmethoxy)-carbonyl]-L- alanyl]-L-proline, phenylmethyl ester.
d) 1-[N-[7-Amino-3-(benzoylamino)-2-oxoheptyl]-L-alanyl]-L-proline, dih ydrochloride 1 -[N-[3-(Benzoylamino)-7-[[(phenylmethoxy)-carbonyl]aminoj-2-oxoheptyl]-N-[(phenylmethoxy)- carbonyl]-L-alanyl]-L-proline, phenylmethyl ester(1.3 g., 1.6 mmole) is dissolved in ethanol (75 ml.) and aqueous hydrochloric acid (iN, 5 ml.). Palladium on carbon catalyst (10%, 450 mg.) is added and the mixture is hydrogenated at atmospheric pressure overnight. The catalyst is filtered off and the solution is evaporated in vacuo. The residue is dissolved in water and lyophilized.The lyophilate is triturated with ether to give 0.6 g. of 1-[N-[7-amino-3-(benzoyl-amino)-2-oxoheptyl]-L-alanyl]-L-proline, hydrochloride; m.p. 80-155 ; [o]2D2 = -50" (c = 1.1, methanol). Rf 0.09 (silica gel, n-butanol/acetic acid/water, 4:1:1).
Anal. calc'd. for C22H32N405 - 2HCl. 1.5 H2O: C,49.63; H,7.00; N,10.52; Cl,13.55 Found: C,49.63; H, 6.82; N, 10.48; Cl, 13.36.
EXAMPLE 3 I-[N-[3-lBenzoylaminoJ-2-oxoheptyll-L-alanyl]-L-proline, monohydrochloride aJ N-Benzoyl-D,L-norleucine D,L-Norleucine (39.3 g., 300 mmole) is taken up into sodium hydroxide (2N, 150 ml.) and while stirring in an ice-bath sodium hydroxide (2N, 150 ml.) and benzoyl chloride (330 mmole, 38.3 ml.) are added over a 30 minute period. The bath is removed and after 1.5 hours the reaction mixture is extracted with either. The aqueous portion is acidified with 2N hydrochloric acid and the crystals filtered to give 68.9 g. of N-benzoyl-D,L-norleucine; m.p. 131-133' (125').
bJ 4Butyl-2-phenyl-564HJ-oxazolone N-Benzoyl-D,L-norleucine (40 g., 170 mmole) is taken up into tetrahydrofuran (300 ml.) with stirring in an ice-bath. To this reaction mixture a solution of dicyclohexylcarbodiimide (38.52 g., 187 mmole) in tetrahydrofuran (195 ml.) is added dropwise over a period of 15 minutes. The ice-bath is removed and stirring is continued at room temperature for an additional 18 hours. Dicyclohexylurea is filtered off and the tetrahydrofuran is concentrated in vacuo. The residue (31.7 g.) is purified on silica in hexane:ether (2:1) to yield 32.1 g. of 4-butyl-2-phenyl-5(4H)-oxazolone.
c) -[Nj3-(Benzoylamin o)-2-oxohep tyl]-N-[(phen ylmethoxy)carbonyl]-L-alan yl]-L-prollne, phen ylmeth yl ester A solution of 1-[N-(carboxymethyl)-N-[(phenylmethoxy)carbonyl]-L-alanyl]-L-proline, phenylmethyl ester (1.41 g., 3mmole), from Example 1(c), in tetrahydrofuran (10 ml.) is cooled in an ice-bath. While stirring, oxalyl chloride (0.32 ml., 3.7 mmole) is added followed by 4 drops of dimethylformamide. The reaction mixture is stirred in the ice-bath for 20 minutes and then at room temperature for one hour. It is evaporated in vacuo, redissolved in tetrahydrofuran (5 ml.) and cooled in an ice-bath.A cold solution of 4-butyl-2-phenyl-5(4H)-oxazolone (0.65 g., 3 mmole) in tetrahydrofuran (5 ml.) is added dropwise followed by triethylamine (0.43 ml., 3.1 mmole). The reaction mixture is stirred at ambient temperature overnight.
After filtering off triethylamine hydrochloride, the tetrahydrofuran solution is concentrated in vacuo. The residue is redissolved in pyridine (3 ml.), 4-dimethylamino pyridine (15 mg.) is added, and the reaction mixture is stirred at room temperature for 3 hours. Acetic acid (3 ml.) is added and the reaction mixture is heated at 100 for 40 minutes. It is then evaporated, redissolved in ethyl acetate and washed with water, saturated sodium bicarbonate, dilute hydrochloric acid, and water. After evaporation, the residue is chromatographed over silica gel using the solvent system ethyl acetate: benzene (4:6) to give 0.8 g. of 1-[N-[3-(benzoyl-amino)-2-oxoheptyl]-N-[(phenylmethoxy)carbonyl]-L-alanyl]-L-proline, phenylmethyl ester.
dJ 1-[N-[3-{BenzoylaminoJ-2-oxoheptyll-L-alanyll-L-proline, m on ohydrochloride 1-[N-[3-(Benzoylamino)-2-oxoheptyl]-N-[(phenylmethoxy)carbonyl]-L-alanyl]-L-proline, phenylmethyl ester (0.96 g., 1.5 mmole) is dissolved in ethanol (75 ml.). Hydrochloric acid (1 N,2ml.) is added followed by palladium on carbon catalyst (10%, 200 mg.). The solution is stirred under an atmosphere of hydrogen overnight. The catalyst is filtered off, the ethanolic solution is evaporated, and the residue is dissolved in water and lyophilized to give 0.62 g. of 1-[N-[3-(benzoylamino)-2-oxoheptyl]-L-alanyl]-L-proline, monohydrochloride; m.p. 86-123 ; [a]f23 = -62.9 (c = 1.05, methanol). Rf 0.57 (silica gel, n-butanol/acetic acid/water; 4:1:1).
Anal. calc'd. for C22H31N305 ' HCl ' 2H2O: C, 53.85; H, 7.40; N, 8.57; Cl, 7.23 Found: C, 53.85; H, 7.20; N, 8.73; Cl, 7.29.
EXAMPLE 4 1-[N-[3-(Benzoylamino)-2-oxo-4-(3-pyridinyl)butyl]-L-alanyl]-L-proline, dih ydrochloride a) 2-{Benzo ylamino)-3-(3-p yridin yl)-2-prop en oic acid 2-Phenyl-4-(3-pyridinylmethylene)-5(4H)-oxazolone (3 g., 12 mmole) [see Griffith et al., J. Org. Chem., Vol.
29, p. 2659] is dissolved in acetic acid (24 ml.) and aqueous hydrochloric acid (0.5 N, 150 ml.). The reaction mixture is stirred overnight at room temperature. It is evaporated and reevaporated from absolute ethanol. It is triturated with tetrahydrofuran, filtered, and the filtered solid is retriturated with absolute ethanol to yield 2.8 g. of 2-(benzoylamino)-3-(3-pyridinyl)-2-propenoic acid; m.p. 215-216 (203 ).
bJ 2-(Benzoylamino)-3-(3-pyridinyl)-2-propanoic acid 2-(Benzoylamino)-3-(3-pyridinyl)-2-propenoic acid (14 g., 46 mmole) is dissolved in water (500 ml.) and hydrogenated using palladium carbon catalyst (10%, 1.8 g.) overnight. The catalyst is filtered off, and the reaction mixture is evaporated to a small volume (100 ml.) and lyophilized to give 13.1 g. of product. The lyophilate is triturated with absolute ethanol-ether mixture and filtered to give 12 g. of 2-(benzoylamino)-3 (3-pyridinyl)-2-propanoic acid; m.p. 99 - 115 .
c) 1-[N-[3-(Benzoylamino)-2-oxo-4-(3-pyridinyl)-butyl]-N-[(phenylmethoxy)carbonyl]-L-alanyl]-L- proline,phenylmethyl ester 1-[N-(Carboxymethyl)-N-[(phenylmethoxy)-carbonyl]-L-alanyl]-L-proline, phenylmethyl ester (6.2 g., 13.1 mmole), from Example 1 (c), is dissolved in tetrahydrofuran (20 ml.) and the solution is stirred in an ice-bath.
Oxalyl chloride is added followed by four drops of dimethylformamide. After stirring this reaction mixture in an ice bath for 20 minutes, it is then stirred at ambient temperature for an additional hour. The solvents are removed in vacuo and this residue is redissolved in tetrahydrofuran (20 ml.).
2-(Benzoylamino)-3-(3-pyridinyl)-2-propanoic acid (4 g., 13 mmole) is suspended in tetrahydrofuran 45 ml.), and while stirring in an ice-bath, triethylamine (1.96 ml., 14 mmole) and dicyclohexylcarbodiimide (2.96 g., 14 mmole) are added. The reaction mixture is stirred at room temprerature overnight. It is then filtered, and the filtrate evaporated to dryness. This residue is dissolved in tetrahydrofuran (30 ml.) and stirred in an ice bath. To this solution is added the above solution of 1-[N-(carboxymethyl)-N-[(phenylmethoxy)carbonyl]-L-alanyl]-L-proline, phenylmethyl ester, acid chloride in tetrahydrofuran (20 ml.). Triethylamine (1.9 ml., 13.6 mmole) is added, and the reaction mixture is stirred at room temperature overnight.It is filtered to remove triethylamine hydrochloride. The filtrate is evaporated in vacuo, redissolved in pyridine (15 ml.), 4-dimethylamino pyridine (65 mg.) is added, and the reaction mixture is stirred at room temperature for 3 hours. Acetic acid (16 ml.) is added and the reaction mixture is heated at 100' for 45 minutes. It is then evaporated, redissolved in ethyl acetate, and washed with aqueous sodium bicarbonate and water. After evaporation, the ethyl acetate extract is chromatographed over silica gel using ethyl acetate for elution to give 3.3 g. of 1 -[N-[3-(benzoylamino)-2-oxo-4-(3-pyridinyl)butyl]-N-[(phenylmethoxy)carbonyl]-L-alanyl]-L- proline, phenylmethyl ester.
dJ 1-[N-[3-(Benzoylamino)-2-oxo-4-(3-pyridinyl)-butyl]-L-alanyl]-L-proline, dih ydrochloride The phenylmethyl ester product from part (c) (2.6 g., 3.84 mmole) is dissolved in ethanol (75 ml.) and aqueous hydrochloric acid (1 N, 8 ml.) is added followed by palladium on carbon catalyst (10%,0.6 g.). After hydrogenation for 16 hours, an additional 0.5 g. of catalyst is added and hydrogenation is continued for 6 more hours. The mixture is filtered, evaporated and combined with a similar reaction product obtained by hydrogenation of 0.8 g. of the ester product of part (c). The hydrogenated material is then chromatographed over LH-20 in water to obtain the homogeneous product. An aqueous solution of this material is treated with aqueous hydrochloric acid (1 N, 3 ml.) and the solution is lyophilized to give 1.0 g. of 1-[N-[3-(benzoylamino)- 2-oxo-4-(3-pyridinyl)butyl]-L-alanyl]-L-proline, dihydrochloride; m.p. 120 - 135 ; [a]2J = -55.5 (c = 1.1, methanol). Rf 0.11 (silica gel; n-butanol/acetic acid/water; 4:1 :1).
Anal calc'd. for C24H28N405 - 2HCl. 2H2O: C, 51.35; H, 5.75; N, 9.98; Cl, 12.63 Found: C, 51.35; H, 5.84; N, 9.96; Cl, 12.84.
EXAMPLE 5 1-[N-[3-(Benzoylamino)-4-(4-hydroxyphenyl)-2-oxobutyl]-L-alanyl]-L-proline, monohydrochloride aJ 2-Phenyl-4-ff4-(phen ylmeth oxy)ph en yllmeth yl]-5(4K)-oxazolon e O-Benzyl-L-tyrosine (11.0 g., 40.5 mmole) is taken into 0.5 N sodium hydroxide (81 ml.) and water (81 ml.) with vigorous stirring in an ice-bath. To this in five equal portions is added a total of 52 ml. of benzoyl chloride, 45 ml. of 1 N sodium hydroxide and an additional 400 ml. of water over a 25 minute period. The bath is removed and the reaction is run for 2 hours at room temperature. The mixture is extracted twice with ethyl acetate. The aqueous portion is filtered, acidified with 1 N hydrochloric acid and the crystals filtered to give 12.9 g. of N-benzoyl-O-benzyl-L-tyrosine; m.p. 166-168 (162").
This N-benzoyl-O-benzyl-L-tryosine (12.76 g., 35 mmole) is taken into dry tetrahydrofuran (50 ml.) with stirring in an ice-bath. To this dicyclohexylcarbodiimide (7.7 g., 37.4 mmole) in tetrahydrofuran (18 ml.) is added dropwise. After 20 minutes, the ice-bath is removed and the reaction proceeds overnight at room temperature. The dicyclohexylurea is filtered off and the filtrate is concentrated to dryness. The crude product is crystallized from ether/hexane to give 10.26 g. of 2-phenyl-4-[[4-(phenylmethoxy)phenyl]methyl]- 5(4H)-oxazolone; m.p. 85-87 (83 ).
b) 1-[N-[3-(Benzoylamino)-2-oxo-4-[4-(phenylmethoxy)-phenyl]butyl]-N-[(phenylmethoxy)carbonyl]-L- alanyll-L-proline, phenylmethyl ester 1-[N-(Carboxymethyl)-N-[(phenylmethoxy)-carbonyl]-L-alanyl]-L-proline, phenylmethyi ester )2.82 g., 6 mmole), from Example 1(c), is dissolved in tetrahydrofuran (20 ml.) and the solution is stirred in an ice-bath.
Oxalyl chloride (0.63 ml., 7.2 mmole) is added followed by four drops of dimethylformamide. After stirring this reaction mixture in an ice-bath for 20 minutes, it is then stirred at ambient temperature for an additonal hour. The solvents are removed in vacuo and the residue is redissolved in tetrahydrofuran (10 ml.) and cooled in an ice-bath. To this cold stirring solution is added a cold solution 2-phenyl-4-[[4-(phenylmethoxy)phenyl]methyl]-5(4H)-oxazolone (2.14 g., 6 mmole) in tetrahydrofuran (40 ml.). Triethylamine (0.84 ml., 6 mmole) is added and a basic atmosphere is maintained throughout the reaction by adding additional necessary amounts of triethylamine. The reaction mixture is stirred t ambient temperature overnight.It is then filtered and the filtrate is evaporated and redissolved in pyridine (7 ml.). 4-Dimethylamino pyridine (30 mg.) is added and the reaction mixture is stirred for 3 hours at room temperature. Acetic acid (7 ml.) is added and the reaction mixture is heated at 100 for 45 minutes. It is then evaporated, the residue is redissolved in ethyl acetate and washed with saturated sodium bicarbonate and dilute hydrochloric acid. The neutral ethyl acetate extract is evaporated and chromatographed over silica gel (300 g.) using the solvent system ethyl acetate:benzene (6.5:3.5) to give 2.7 g. of 1-[N-[3-(benzoylamino)-2-oxo-4-[4-(phenymethoxy)-phenyl]butyl]- N-[(phenylmethoxy)carbonyl]-L-alanyl]-L-proline, phenylmethyl ester.
cJ 1-[N-[3-(Benzoylamino)-4-(4-hydroxyphenyl)-2-oxobutyl]-L-alanyl]-L-proline, mon oh ydrochloride The ester product from part (b) (1.8 g., 2.26 mmole) is dissolved in ethanol (150 ml.) containing aqueous hydrochoric acid (IN, 3.5 ml.). Palladium on carbon catalyst (10%, 500 mg.) is added and the solution is stirred under an atmosphere of hydrogen overnight. It is evaporated, dissolved in water, and lyophilized to give 1-[N-[3-(benzoylamino)-4-(4-hydroxyphenyl-2-oxobutyl]-L-alanyl]-L-proline, monohydrochloride; m.p.
118-152"; [0L]2c2 = - 63.1' (c = 1.07, methanol). Ff0.47 (silica gel, n-butanol/acetic acid/water; 4:1:1).
Anal. calc'd. for C28H29N3O8 - HCI - H2O: C,57.42; H, 6.16; N,8.04; Cl, 6.78 Found: C,57.42; H, 6.03; N, 8.04; Cl, 7.11.
EXAMPLES 6-62 Following the procedure of Examples 1-3 and 5, the peptide ester shown in Col. I is treated to give the carboxymethyl peptide ester shown in Col. II. Conversion to its acid chloride and further reaction with the oxazolone of Col. Ill yields the N-protected ester product of Col. IV. Removal of the N-protecting group and the ester group yields the final product of Col. V wherein R6 is hydrogen.
Col. I
Col.II
col.III
Col.IV
Col. V
ExaX!plc Ri .Rz L. x R1 2 3.
OH 6 H C - 0 52 . 0 MXQIZ (L) H 7 H3C- cH2 H- OC(CH3) 3 7 U3 (CN- z~ A H 81 8 (o > -(CH1)?' 3CH2" ,COOCH2 9 C13CH2C- (41X2 ( {LP IL) H 10 (P2 (ca2 ( ( 2) 2 rXN 9 Cl CH NH(LOOC(CH?)3 Gc0H2 (CH2)2 I )(L) H 11 H3C- & ' 12 g3C- tCH2) 3- ( > $) < ) H 13 H5C2 iTL Th2 S COOCH20 1(L) H
Example ' q R2 R2 x 0 0' 0 14 H > C- /1 ( 2.2 W 2 4 (E(M9 H 15 H3C-(CH2)2- olol""3 a H24 H 16 HJCI I 1 16 H3C CH2 I I /1 17 F3C- H3Co 4 r > 2 5 S m S S F3. H3Co 2 -NCli2 0 o NH-C-C H le H C- 8 W N t H3C s 19 wyIcca2)2- 9 H Ir {L) 4 H (L) 20 H2COH2C- . Ncii2 omThoo 20r,coH,c: 21 > H2- H3C- H3C -NH-CH-COOM CH2 cH(CH3)2
R3 x Exaz:1e R1 R2.
~ ~ ~ ~ 22 H5 2 s H3C- g OCN(CN3)2 0 0cNccH3)2 23 H3C- g CH2- H5C2- -N < 2 4 23 HJC- H CL) 2 H2C 24 H3C- H3C-(H2C)3- H(L) < 25 \ H3C- EIC- -1, F3C 2 o CH 4 H CL) 26 F3C- 0 (CR2)3 -N H (L) 27 H3C- N 26 H5C2- CcR2)3- 2)3 ?rkN J 29 ' 4 lcH2)4- rs N 30 H3C-- Go &commat; &verbar;;tL - 2 4
Example R1 R2 R3 X 31 H3C- Go H3CS > CH2- -N n mLiOOCH2 H 32 5 2 7 H5C2- (TL G5O2 - cooC CL) R2 33 H3C- Go CH2- -;D COOCH24) I 7Oo H 34 2 &commat; H5C2- N GcoH2 -CH2- 4 (òjoc H H 35 H3C- CR ' coocHz H 36 C-HN- (H2CM rm 02N-NH CH2- 2&commat;) H I.
O S S 37 CeH2COCHN (H2C)4- Go. -::H2- ss (L) Y 38 H2COH2C Go b H2C- > &commat; H H 39 %:2;).a2c (ml (cH2) 2" 2C -N+82 < ) H
Example R1 R2 R3 X 40 (O (MN1H2C (% H2- -N I - CLH2 H H 41 Nx H2C- CH2- (ThCH2-. i;cOoCH2 CH2X3 42 H3C-S- (H2C)2- Go > CCH2)3- ;{LCOOC)H2 -N--C COOCH2-(n? RN 43 H3C- Go /CHN(H2C)3 OZN-HN "NCc)H2 H 44 H3C- Go eH29 2 1 rooM-(n7 o'Z 45 H3C- H2C- S 45 H3C' (L] COOCH7-j) H $)CccCH2 H 46 -NH-CH,-CooCH-5; -NHCHOOCH2 47 F3C- ( (CR2)4- 1(L) CH3 48.2C- g)~ H- ---COOCH23 CL) CR 12.
CHCH3)2 49 H C - Go tCH2 -NH-CH-COOCH t CH2 (Do OCH24)
Example R1 R2 R3 X 50 H3C- Go (CH2- -NH-CH-COOCH CH2 X OCH2t SOCH2 51 H 3C- Go -CH2 - -NHcH-COOCH2 cH2TDlNO H 52 )^H2C- > Go CR- -NH-CH-COOCH; 1(L) CH"---N CH2vJ CH24 3 ( > H3C-(H2C)5- l NH-CH-COOCH2 CL) (CH2) 4-NHCOCH2t 0 5Q ( > GO (L) -NH-CH-COOCH2 CR2-SC H2 55 H3C2- &commat; 2 )eHi (L} NH NHCjH(LCOOC)R2 I(L) 3 sRNO2 NNN02 56 H3C- Go ca2 -NHCH-COH2 ( H ) -C-NH o 0 o "2-C-0-CH.9'C'CZB5 d Fm 58 H3C- Go (B- K ss S.0 II H CH(CH3)2
Example Rl R2 3 X 0 II A o o 59 H3C- (cH2)3- tCH+C-C2N5 " "";; 60 f\ 0 (m- .01 0 SCR2 2 -NC-O-CH sCH2 sC It CL) 'C-O-CHZ-O-C-C 2 3 3 H 61 H3C- 0 o ImlOl 2 -N I(L) C+CH2+Ce H 62 H3C-(H - Go Go H2 -Nn1 li -N ~1 7(L) H The R1 protecting groups in Examples 20,36 to 39 and 41, the Rg protecting groups in Examples 43 and 44, and the F5 protecting groups in Examples 49, 50, and 52 to 55 are removed as the last step in the synthesis.
The Rg ester groups shown in Examples 57 to 62 are not removed.
EXAMPLE 63 1-[N-[(S)-3-(Benzoylamino)-2-oxo-4-phenylbutyl]-L-alanyl]-L-proline, monohydrochloride a) (S)-3-Amino- i-chloro-4-phenyl-2-butanone, hydrogen bromide (S)-[3-Chloro-2-oxo-1 -(phenyl methyl)propyl]-ca rbamic acid, phenylmethyl ester (51.4 g.) is dissolved in a mixture of acetic acid (252 ml.) and hydrogen bromide in acetic acid (3.45 N, 348 ml.) and kept at room temperature for 1.5 hours. The reaction mixture is then concentrated in vacuo and precipitated with ether to obtain 36.6 g. of (S)-3-amino-1-chloro-4-phenyl-2-butanone, hydrogen bromide; m.p. (175 ) 177-179".
b) (S)-N-[3-Chloro-2-oxo- i-(phenylmethyl)prop ylj-benzamide (S)-3-Amino-1-chloro-4-phenyl-2-butanone, hydrogen bromide (36.3 g., 130.3 mmole) is suspended in 520 ml. of dry tetrahydrofuran and 18.2 ml. oftriethylamine (130.3 mmole) with stirring for ten minutes. The mixture is placed in an ice bath and 15.2 ml. of benzoyl chloride is added followed by 10.95 g. of sodium bicarbonate. After 5 minutes the ice bath is removed and the reaction mixture is kept at room temperature for 1.5 hours. The reaction mixture is then concentrated in vacuo and the residue taken up in 11. of aqueous methanol (10% water).The precipitate is collected, filtered and washed with methanol to obtain 25.3 g. of (S)-N-[3-chloro-2-oxo-1 -(phenyl methyl)propyl]-benzamide; m.p. (160 ) 170 -172 (dec.); [a]203 = -1 29(c 1.7, dimethylformamide).
c) 1-[N-[(S)-3-(Benzoylamino)-2-oxo-4-phenylbutyl]-L-alanyl]-L-proline, 1, t-dimethyl-ethyl ester L-Alanyl-L-proline, 1,1-dimethylethyl ester (2.42 g., 10 mmole), sodium bicarbonate (840 mg.) and (S)-N-[3-chloro-2-oxo-1-(phenylmethyl)propyl]benzamide (3.01 g.) are combined in 50 ml. of dimethylforma mide under an argon atmosphere at room temperature with stirring overnight. The reaction mixture is then concentrated in vacuo to about half its original volume and the residue is taken up in ethyl acetate and washed with saturated sodium bicarbonate to give 2.25 g. of crude product. This material is taken up in ethyl acetate: methanol (95:5) and applied to a silica gel column (135 g.) and eluted with ethyl acetate: methanol (95:5) to give 860 mg. of 1-[N-[(S)-3-(benzoylamino)-2-oxo-4-phenylbutyl]-L-alanyl]-L-proline,1,1- dimethylethyl ester.
d) 1-[N-[(S)-3-(Benzoylamino)-2-oxo-4-phenyl-butyl]-L-alanyl]-L-proline, monohydrochloride 1-[N-[(S)-3-(Benzoylamino)-2-oxo-4-phenylbutyl]-L-alanyl]-L-proline, 1,1 -dimethyl-ethyl ester (740 mg., 1.46 mmole) is dissolved in a solution of hydrogen chloride in acetic acid (1.5 N, 10 ml.) and kept at room temperature for 30 minutes. it is then concentrated, taken into water, filtered and lyophilized to obtain 600 mg. of 1-[N-(S)-3-(benzoylamino)-2-oxo-4-phenylbutyl]-L-alanyl]-L-proline, monohydrochloride; m.p 83 163 ;[&alpha;]D25=-109 (c = 1.04, methanol). Rf 0.6 (silica gel; butanol/acetic acid/water, 4:1 :1).
Anal. calc'd. for C25H29N305 . HCl 1.65 H2O: C, 57.99; H, 6.48; N, 8.12; Cl, 6.85 Found: C, 57.99; H, 6.39; N, 8.09; Cl, 6.95.
EXAMPLE 64 (S)-1-[N2-[3-(Benzoylamino)-2-oxo-4-phenylbutyl]-L-lysyl]-L-proline, dihydrochloride a) l-[N6-[( I, 1-Dimethylethoxy)carbonyl]-N2-[(phenylmethoxy)carbonyl]-L-lysyl]-L-proline, 1, 1-dimethyleth yI ester N6-[(1,1-Dimethylethoxy)carbonyl]-N2-[(phenylmethoxy)carbonyl]-L-lysine (9.51 g.) and hydroxybenzotriazole (3.825 g.) are taken into 25 ml. of dimethylformamide with stirring in an ice-bath under an argon atmosphere. To this is added L-proline, 1,1-dimethylethyl ester (4.49 g.) followed by N,N'diisopropylethylamine (2.2 ml.) and dicyclohexylcarbodiimide (5.15 g.). After 15 minutes the bath is removed and the reaction is allowed to proceed for 6.5 hour at room temperature. The dimethylformamide is removed in vacuo. The residue is taken into ethyl acetate and the dicyclohexylurea is filtered off.The filtrate is washed neutral with 10% postassium bisulfate and saturated sodium bicarbonate. The crude product (13.26 g.) is purified on silica gel column eluting with ethyl acetate:hexane (2:1) to give 13.0 g. of 1-[N6-[(1,1- dimethylethoxy)carbonyl]-N2-[(phenylmethoxy)carbonyl]-L-lysyl]-L-proline,1,1-dimethylethyl ester.
b)(S)- I-[N2-[3-(Benzoylamino)-2-oxo-4-phenylbutyl]-N6-[(1,1-dimethylethoxy)carbonyl]-L-lysyl]-L-proline, 1, 1-dimethylethyl ester The ester product from part (a) is reduced in ethanol with palladium on carbon catalyst (10%) to yield 3.99 g. of 1-[N6-[1,1-dimethylethoxy)-carbonyl]-L-lysyl]-L-proline, 1,1-dimethylethyl ester. This material is taken into 40 ml. of dimethylformamide and treated with (S)-N-[3-chloro-2-oxo-1-(phenylmethyl)propyl]benzamide (3.01 g.), from Example 63(b), and sodium bicarbonate (840 mg.). After stirring for 18 hours at room temperature, the reaction mixture is concentrated in vacuo, taken into ethyl acetate and washed with saturated sodium bicarbonate.The crude product (7.0g.) is purified on a silica gel column eluting with ethyl acetate: 1% methanol to give 1.7 g. of (S)-1-lN2-[3-(benzoylamino)-2-oxo-4phenylbutyl]-N6-[(1,1- dimethylethoxy)carbonyl]-L-lysyl]-L-proline,1,1-dimethylethyl ester.
c) (S)-1-[N2-[3-(Benzoylamino)-2-oxo-4-phenylbutyl]-L-lysyl]-L-proline, dihydrochloride The ester product from part (b) (1.6 g.) is treated for 30 minutes at room temperature with 20 ml. of 1.5 N hydrochloric acid:acetic acid, concentrated to dryness, and triturated to a solid with ether to give 1.37 g. of crude product. This material is taken into water, millipore filtered, and lyophilized to give 1.28 g. of product.
Further purification is performed on an LH20 column in water to give 740 mg. of (S)-1-[N2-[3-(benzoylamino)2-oxo-4-phenylbutyl]-L-lysyl]-L-proline, dihydrochloride; m.p. 120-180"; [a]2D5 = -84.8 (c = 1.05, methanol).
Rf 0.61 (trace at 0.9) (silica gel, chloroform/methanol/ acetic acid, 60, 40, 38% 20).
Anal. calc'd for C28H36N4Os 2HCI 3H2O: C,52.98; H, 6.98; N,8.83; Cl, 11.17 Found: C, 52.98; H, 6.93; N, 8.66; Cl, 11.31.
EXAMPLE 65 N-[N-[[(S)-3-(Benzoylamino)-2-oxo-4-phenylbutyl]-L-alanyl]-N-cyclohexylglycine, monohydrochloride a) N-Cyclohexylglycine, 1, 1-dimethylethyl ester Cyclohexylamine (70.35 ml.) and sodium bicarbonate (12.9 g.) are suspended with stirring in 200 ml. of absolute ethanol while stirring in an ice-bath. To this is added bromoacetic acid, 1,1-dimethylethyl ester (20.78 ml.) dropwise. The ice-bath is removed. After 24 hours at room temperature, the reaction mixture is concentrated to dryness, taken into chloroform and washed with water. The crude product (42 g.) is chromatographed on silica gel eluting with ethyl acetate: hexane (2:1) to give 27.4 g. of N-cyclohexylglycine, 1,1 -dimethylethyl ester.
b) N-Cyclohexyl-N-[N-[(phenylmethoxy)carbonyl]-L-alanyl]glycine, 1, i-dim eth yleth yI ester N-[(Phenylmethoxy)carbonyl]-L-alanine (4.46 g.), N-cyclohexylglycine,1,1-dimethylethyl ester (4.26 g.), hydroxybenzotriazole (3.06 g.), dicyclohexylcarbodiimide (4.12 g.), and triethylamine (2.8 ml.) are stirred in 40 ml. of dimethylformamide at room temperature for 20 hours. The reaction mixture is then concentrated in vacuo, taken into ethyl acetate, the dicyclohexylurea is filtered off, and the filtrate is washed neutral with 10% potassium bisulfate and saturated sodium bicarbonate to give 5.9 g. of crude product. Crystallization from ether:hexane yields 3.97 g. of N-cyclohexyl-N-[N-[(phenylmethoxy)carbonyl]-L-alanyl]glycine,1,1- dimethylethyl ester; m.p. 104-105 .
c) N-(L-Alanyl)-N-cyclohexylglycine, t, 1-dimethylethylester The ester product from part (b) (3.9 g.) is taken into methanol with palladium on carbon catalyst (10%, 700 mg.) and stirred under hydrogen atmosphere for 4 hours. The reaction mixture is filtered and concentrated to dryness to give 2.65 g. of crude N-(L-alanyl)-N-cyclohexylglycine, 1,1 -dimethylethyl ester.
d) N-[N-[[(S)-3-(Benzoylamino)-2-oxo-4-phenylbutyl]-L-alanyl]-N-cyclohexylglycine, 1,1-dimethylethyl ester The crude ester product from part (c) (2.6 g.), sodium bicarbonate (764 mg.), and (S)-N-[3-chloro-2-oxo-1 (phenylmethyl)propyl]benzamide (2.75 g.), from Example 63(b), are stirred for 20 hours in 25 ml. of dimethylformamide. The reaction mixture is concentrated to dryness, taken into ethyl acetate, and washed with saturated sodium carbonate to give 4.7 g. of crude product. Purification on a silica gel column eluting with ethyl acetate:methanol (99:1) yields 1.5 g. of N-[N-[[(S)-3-(benzoylamino)-2-oxo-4-phenylbutyl]-L- alanyl]-N-cyclohexylglycine,1,1-dimethylethyl ester.
eJ N-[N-[[(S)-3-(Benzoylamino)-2-oxo-4-phenyl-butyl]-L-alanyl]-N-cyclohexylglycine, m onoh ydrochloride The ester product from part(d) (500 mg.) is treated for 30 minutes with 5 ml. of 1.5 N hydrochloric acid:acetic acid and then concentrated to dryness at room temperature. The crude product is taken into methanol and purified on an LH20 column to yield 413 mg. of product. This is made semi-crystalline in acetonitrile:ether to give N-[N-[[(S)-3-(benzoylamino)-2-oxo-4-phenylbutyl]-L-alanyl] -N-cyclohexylglycine, monohydrochloride; m.p. 154-157' (132 ); [ X]23 = -67.4 (c = 1.35, methanol). Rf 0.60 (minor impurity at 0.92) (silica gel, chloroform:methanol:conc. ammonia, 30:10:2).
Anal. calc'd. for C28H35N3O5. HCl H2O C, 61.35; H, 6.99; N, 7.67; Cl, 6.47 Found: C, 61.08; H, 6.79; N, 7.65; Cl, 6.46.
EXAMPLE 66 N-[N-[[(S)-3-(Benzoylamino)-2-oxo-4-phenylbutyl]-L-alanyl]-N-phenylglycine, m onoh ydrochloride a) N-Phenylglycine, 1,1-dimethylethyl ester A solution oftriethylamine (11.25 g., 0.11 mole) and aniline (9.3 g., 0.10 mole) in ether (100 ml.) under an argon atmosphere is cooled to 0 in an ice-bath. To this is added bromoacetic acid, 1,1-dimethylethyl ester (18 g., 0.093 mole) over a period of 30 minutes. The resulting mixture is stirred at 0 for one hour, then warmed to room temperature, and stirred overnight.The solution is filtered and rinsed with ether and the filtrate concentrated to yield 6.9 g. of a yellow oil. Ff0.6, 0.7 (silica gel, ethyl acetate). Chromatography on LPS-1 using hexane;ethyl acetate (7:3) as eluant gives 2.3 g. of N-phenylglycine, 1,1 -dimethylethyl ester as a pale yellow liquid. Rf 0.7 (silica gel, ethyl acetate).
b) N-Phenyl-N-[N-(phenylmethoxy)carbonyl]-L-alanyl]glycine, 1,1-dimethylethyl ester A solution of N-[(phenylmethoxy)carbonyl]-L-alanine (2.8, 12.7 mmole) in dry tetrahydrofuran (50 ml.) under argon is cooled in a dry ice-ethanol bath. To this is added N-methylmorpholine (1.28 g., 12.7 mmole) and isobutylchloroformate (1.73 g., 12.7 mmole). After 20 minutes N-phenylglycine, 1,1-dimethylethyl ester (3.7 g., 12.7 mmole) is added. The resulting mixture is stirred at -20 for one hour, then at room temperature overnight. The mixture is partitioned between ethyl acetate and 1 N hydrochloric acid.The organic layer is washed successively with 1 N hydrochloric acid and 10% sodium bicarbonate, dried (MgSO4), and concentrated. Chromatography on LPS-1 eluting with a gradient of ethyl acetate:hexane (3:1 # 1:1) gives 4.0 g. of N-phenyl-N-[N-[(phenylmethoxy) carbonyl]-L-alanyl]glycine, 1,1-dimethylethyl ester as a clear oil. Rf 0.4 (silica gel, ethyl acetate).
c) N-(L-Alanyl)-N-phenylglycine, 1,1-dimethyl-ethylester A solution of the ester product from part (b) (4.0 g., 9.7 mmole) in ethanol (125 ml.) and 10% palladium on carbon catalyst is stirred under a flow of hydrogen for 18 hours. The solution is filtered, concentrated, dissolved in ethyl acetate and extracted with 1 N hydrochloric acid. The aqueous layer is treated with sodium bicarbonate until basic and extracted with ethyl acetate. The combined ethyl acetate extracts are dried (MgSO4) and concentrated to give 1.3 g. of N-(L-alanyl)-N-phenylglycine,1,1-dimethylethyl ester as a white solid. Rf 0.52, minor spot at 0.64 (silica gel, ethyl acetate: methanol; 1:1).
d)N-[N-[[(S)-3-(Benzoylamino)-2-oxo-4-phenylbutyl]-L-alanyl]-N-phenylglycine, 7, 1-dimethylethyl ester To a stirring solution of (S)-N-[3-chloro-2-oxo-1-(phenylmethyl)propyl]benzamide (1.4 g., 4.7 mmole), from Example 63(b), and N-(L-alanyl)-N-phenylglycine, 1,1-dimethylethyl ester (1.3 g., 4.7 mmole) in dry dimethylformamide is added sodium bicarbonate (0.38 g., 4.7 mmole) and sodium iodide (0.7 g., 4.7 mmole).
After stirring overnight at room temperature, the mixture is concentrated, dissolved in ethyl acetate and filtered. The filtrate is washed with 10% sodium bicarbonate, dried (MgSO4), and concentrated to a yellow oil. Chromatography on LPS-1 eluting with a gradient of ethyl acetate: hexane (1:1) to ethyl acetate gives 1.8 g. of N-[N-[[(S)-3-(benzoylamino)-2-oxo-4-phenylbutylj-L-alanyl]-N-phenylglycine, 1,1 -dimethylethyl ester.
Rf 0.34 (silica gel, ethyl acetate).
e) N-[IV-ISJ3-(Benzo vlamin o)-2-oxo-4-phen ylb utyli-L -alan yI]-N-phenylglycine, monohydrochloride A solution of the ester product from part (d) (1.6g.,2.9mmole) in hydrochloric acid/acetic acid (1.77 N, 17.0 ml.) is stirred at room temperature for 30 minutes. The solution is concentrated and the residue is triturated with ether to give a pale yellow solid. Recrystallization from methanol/ether gives 0.84 g. of N-[N-[[(S)-3 (benzoylamino)-2-oxo-4-phenylbutyl]-L-alanyl]-N-phenylglycine, monohydrochloride as a white, crystalline solid, m.p. 147 - 159 (dec.). Rf 0.8 (silica gel, butanol:acetic acid:water; 1:1:1). [oi]D = -12.7 (c = 1.5, methanol).
Anal. calc'd. for C28H29N305 . HCl. 0.65 H2O: C, 62.77; H, 5.89; N, 7.84; Cl, 6.62 Found: C, 62.77; H, 5.70; N, 7.84; Cl, 6.12.
EXAMPLE 67 (S)-1-[N-[[3-(Benzoylamino)-2-oxo-4-phenylbutyl]-N-methyl-L-alanyl]-L-proline, monoh ydrochloride a) N-[(Phenylmethoxy)carbonyl]-L-alanine L-Alanine (89.1 g., 1 mole) is dissolved in 2N sodium hydroxide (500 ml.) and chilled to 0 . To this is added simultaneously dropwise over a one hour period benzylchloroformate (204.5 g., 1.2 mole) and 4N sodium hydroxide (250 mi.). The reaction mixture is stirred overnight (0 to room temperature), and washed with ethyl acetate (2 x 500 ml.). The aqueous portion is acidified to pH 2.0 with 6N hydrochloric acid and extracted with ethyl acetate (3 x 600 ml.).The combined ethyl acetate extracts are dried (Na2SO4), concentrated on a rotary evaporator, and the solid residue is triturated with petroleum ether to give 194.0 g. of N-[(phenylmethoxy)carbonyl]-L-alanine as a white solid.
b) N-Methyl-N-[(phenylmethoxy)carbonyl]-L-alanine To a cold (0 ) solution of N-[(phenylmethoxy)-carbonyl]-L-alanine (22.3 g., 0.1 mole) and methyl iodide (50 ml., 0.8 mole) in tetrahydrofuran (250 ml.) is added sodium hydride dispersion (14.25 g., 0.3 mole) cautiously with gentle stirring. The suspension is stirred overnight under a nitrogen atmoshere (0 # room temperature), slowly poured into saturated sodium bicarbonate (200 ml.), diluted with ethyl acetate (300 ml.) and the layers separated. The organic layer is extracted once more with saturated sodium bicarbonate. The combined aqueous layers are acidified to pH 2.0 with 10% potassium bisulfate and extracted with ethyl acetate.The combined ethyl acetate extracts are dried (Na2SO4) and concentrated in vacuo into a dark oily residue (23.0 g.).
This crude acid is treated with dicyclohexylamine (20 ml.) in ether (150 ml.). The resulting crude dicyclohexylamine salt is collected (37.0 g.), recrystallized from chloroform/ether (35.0 g.), and converted back to the acid by partitioning between 1 N hydrochloric acid/ethyl acetate, yielding a pale yellow oil, which crystallizes on standing (17.4 g.).
Recrystallization (11.2 g.) from ethyl acetate/petroleum ether gives 4.0 g. of N-methyl-N [(phenylmethoxy)carbonyl]-L-alanine as a white crystalline product; m.p. 65-66.5'; [a]2o5 = -31.1 (c = 2, acetic acid).
cJ 1-[N-Methyl-N-[(phenylmethoxyJcarbonyll-L-alanyll-L-proline, 1,1-dimethyethyl ester To a solution of N-methyl-N-[(phenylmethoxy)-carbonyl]-L-alanine (4.74 g., 20 mole) in distilled tetrahydrofuran (50 ml.) is added L-proline, 1,1-dimethylethyl ester (3.42 g., 20 mole), hydroxybenzotriazole hydrate (3.06 g., 20 mole) and dicyclohexylcarbodiimide (4.12 g., 20 mole). The reaction mixture is stirred overnight, the precipitated dicyclohexylurea is filtered off, and the filtrate is concentrated.The residue is dissolved in ethyl acetate (50 ml.) and washed with saturated sodium bicarbonate (twice),10% potassium bisulfate (twice), and water (twice), dried (Na2SO4), and concentrated to give 6.4 g. of 1-[N-methyl-N-[(phenylmethoxy)carbonyl]-L-alanyl]-L-proline,1,1-dimethylethyl ester as an oily residue.
dJ 1-(N-Methyl-L-alanyl]-L-proline, 1,1-dimethylethyl ester A mixture of the ester product from part (c) (6.4 g., 16.4 mole) and 0.8 g. of 10% palladium on carbon catalyst in ethanol (95%, 150 ml.) is hydrogenated at atmospheric pressure overnight. The catalyst is removed by filtration and the filtrate is evaporated. The resulting oily residue solidifies upon drying in high vacuum into an oily solid residue (3.8 g.). Trituration with ether affords 1.5 g., of 1-(N-methyl-L-alanyl)-L proline, 1,1-dimethylethyl ester, monohydrochloride as a white solid; Rf0.44 (silica gel, 20% methanol/ chloroform). [&alpha;]D25 = -102.1 (c = 2, acetic acid).
The ether filtrate affords 2.3 g. of 1 -(N-methyl-L-alanyl)-L-proline,1,1-dimethylethyl ester as an oil; Rf 0.44 (silica gel, 20% methanol/chloroform). [a]26" = -101.6 (c = 2, acetic acid) e)(S)-1-[N-[[3-(Benzoylamino)-2-oxo-4-phenylbutyl]-N-methyl-L-alanyl]-L-proline, 1, l-dimethvethyl ester A reaction mixture of 1-(N-methyl-L-alanyl)-L-proline, 1,1-dimethylethyl ester (2.1 g., 8.19 mole), (S)-N-[3-chloro-2-oxo-1 -(phenylmethyl)propyl]-benzamide (2.46 g., 8.19 mole), from Example 63(b), excess sodium bicarbonate, and sodium iodide (1.22 g., 8.10 mmole) in dimethylformamide (15 ml.) is stirred at room temperature overnight under a nitrogen atmosphere. The reaction mixture is concentrated, the residue is partitioned between water/ethyl acetate, the layers are separated, and the aqueous layer is extracted once more with ethyl acetate. The combined organic extracts are washed with saturated sodium bicarbonate and water, dried (Na2SO4), and concentrated into an oily residue (3.5 g.). Flash chromatography (200 g. silica gel, 1% methanol/ethyl acetate) affords 2.8 g. of (S)-1-[N-[[3-(benzoylamino)-2-oxo-4-phenylbutyl]-N-methyl-L- alanyl]-L-proline,1,1-dimethylethyl ester as a yellow oil.
fl (S)-1-[N-[[3-(Benzoylamino)-2-oxo-4-phenylbutyl]-N-methyl-L-alanyl]-L-proline, monohydrochloride The ester product form part (e) (1.4 g., 2.7 mmole) is treated with 2N hydrochoric acid/acetic acid (20 ml.).
After stirring for 2 hours at room temperature, the reaction mixture is concentrated under reduced pressure and the resulting oily residue is triturated with ether (four times) to give 1.05 g. of(s)-i -[N-[[3- (benzoylamino)-2-oxo-4-phenylbutyl]-N-methyl-L-alanyl]-L-proline, monohydrochloride as an off-white solid; m.p. 125 - 135 ; Rf 0.24 (silica gel, n-butanol/acetic acid/water; 4:1:1). [a|2DS = - 87 (c=1, methanol).
Anal. calc'd. for C26H31 N305 HCl 0.7 H2O: C, 60.68; H, 6.41; N, 8.16; Cl, 6.88 Found: C, 60.68; H, 6.36; N, 7.95; Cl, 6.48.
EXAMPLE 68 (S)-1-[N-[3-(Benzoylamino)-2-oxo-4-phenylbutyl]-4-phenylglycyl]-L-proline, hydrochloride (20:3) a) l-(Bromoacetyl)-L-proline, 1, 1-dimethylethyl ester To a chilled (-10 ) solution of L-proline, 1,1-dimethylethyl ester (34.2 g., 0.2 mole) in methylene chloride (250 ml.) is added diisopropylethylamine (38.3 ml., 0.22 mole) and bromoacetyl chloride (16.5 ml., 0.2 mole) dropwise over a 20 minute period while keeping the temperature between -10 to -5 . The dark reaction mixture is stirred overnight (-10' to room temperature) and concentrated under reduced pressure.The oily residue is redissolved in ethyl acetate, washed with saturated sodium bicarbonate (twice), 10% potassium bisulfate (twice), and water (twice), dried (Na2SO4), and concentrated into a dark oily residue (28.0 g.). Flash chromatography (LPS-1 silica gel, 10% ethyl acetate/methylene chloride) affords 11.0 g. of 1-(bromoacetyl)- L-proline, 1,1 -dimethylethyl ester as a pale yellow oil.
b) l-(N-Phenylglycyl)-L-proline, 1,1-dimethylethyl ester To a solution of 1-(bromoacetyl)-L-proline,1,1-dimethylethyl ester (2.1 g., 7.5 mmole) in distilled tetrahydrofuran (40 ml.) is added aniline (1.5 g., 15 mmole) and the reaction mixture is stirred overnight under nitrogen. The reaction mixture is diluted with ethyl acetate (200 ml.), washed with saturated sodium bicarbonate (2 x 50 ml.) and water (twice), dried (Na2SO4), and concentrated in vacuo into a dark oily residue (4.0 g.). Flash chromatography (LPS-1 silica gel, 10% ethyl acetate/methylene chloride) affords 2.2 g. of 1-(N-phenylglycyl)-L-proline, 1,1-dimethylethyl ester as a dark oil which solidifies upon drying in high vacuum.
c) {S)- 1-[N-[3-(Benzoylamino)-2-oxo-4-phenylbutyl]-N-phenylglycyl]-L-proline, 1,1-dimethylethyl ester A reaction mixture of 1-(N-phenylgycyl)-L-proline,1,1-dimethylethyl ester (1.06 g., 3.5 mmole), (S)-N-[3 chloro-2-oxo-1 -(phenylmethyl) propyl]benzamide (1.06 g., 3.5 mmole), from Example 63(b), excess sodium bicarbonate, and sodium iodide (0.52 g., 3.5 mmole) in dimethylformamide (10 ml.) is stirred at room temperature under a nitrogen atmosphere overnight. The reaction mixture is poured into water (50 ml.) and extracted with ethyl acetate (3 x 50 ml.).The combined ethyl acetate extracts are washed with saturated sodium bicarbonate (twice) and water (three times), dried (Na2SO4), and concentrated under reduced pressure to give a dark oily residue (2.0 g.). flash chromatography (LPS-1 silica gel, 5% ethyl acetate/methylene chloride to 15% ethyl acetate/methylene chloride) affords 0.3 g., of (S)-1-[N-[3- (benzoylamino)-2-oxo-4-phenylbutyl]-N-phenylglycyl]-L-proline,1,1-dimethylethyl ester as a pale yellow foam.
d) (S)-1-[N-[3-(Benzoylamino)-2-oxo-4-phenylbutyl]-N-phenylglycyl]-L-proline, hydrochloride (20:3) The ester product from part (c) (0.28 g., 0.49 mmole) is treated with 2N hydrochloric acid/acetic acid. After stirring for one hour at room temperature,the reaction mixture is concentrated under reduced pressure and the resulting oily residue is triturated with ether (4 x) to give 0.14 g. of (S)-l -[N-[3-(benzoylamino)-2-oxo-4 phenylbutyl]-N-phenylglycyl]-L-proline, hydrochloride (20:3) as an off-white solid; m.p. 110- 140 ; Rf 0.76 (minor spot at 0.53) (silica gel, n-butanol/acetic acid/water; 3:1:1).
Anal. calc'd. for C30H31N3O5.0.15 HCl 0.5 H2O: C, 68.22; H, 6.13; N,7.95; Cl, 1.00 Found: C, 68.22; H, 6.00; N, 8.25; Cl, 0.99.
EXAMPLES 69-90 Following the procedure of Examples 63 to 68 but employing the ketone shown in Col. I, the acid chloride shown in Col. II, and the peptide ester shown in Col. ill, one obtains the ester product shown in Col. IV.
Removal of the R6 ester group and any other protecting groups give the corresponding final product in acid form.
Col.I
Col. II
Col.III
Col. IV
Example R3 R2 R1 X R T"27 S S 69 0cR2- 2 II- - -N 4 CcoC(CR ;)3 9 ç 70 9 CH2- H- {)cOC (cur3)3 H < ) 71 &commat; (CH2)4 H3C H H- -N 4 NOC(CH3)3 H3C H -) 72 (Th 2 (CH ) H c- -N ) 83C CR2- I CL) 3 H
Example R3 R2 R1 X 73 DR2 Go F3C 73 D CN2 ( > F3C % H.{L) 8 -W 74 8 8; CR2- H -;r-un2' COOC(CH3)3 H-.
75 H3C-(H C) - CH2' H3C- -N-CH2-COOC(CH3) 3 H (Do 0 76 Go , ( > (H2C) " {H2C) 4 (CH2J 2 -cooc (CHJ)J 11 II S 5 77 ~ ( > 2 RN\\ ) 3 C-RN- (H2C) 3" 3 COOC(CtI,) H 02N-RN H 78 ml CR H C 78 HN 3 0 N-RN 3 23 COOC L 2 C-aN-CR C) H 79 T\----;;rH2C' N > CH2- H3C' /\( 0 N , -NtLiOOC II- (CN3 ) 3 N H H 80 H2C02O ( > 2 (OCH2- H3C' 2 (CR2) - < CooCCCR3)3 H H 81 CR2- H- NH-CH-COOC (CH3) 3 H3C IC 3 CH20CHi
Example R3 R2 q X R 82 Go (112" (gH - NRC%C)OOC (CR3)3 H CR (D2 B3 T CH2- H- NRClR(LOOC(CR3)3 H5C2 FHZ cCR2 84 (01 2 H3C- -NH-CH-COOC (CH3) 3 H1 N CIWO 85 06 2 Go H3C- -NH-CH-COOC (CH3) 3 H I (L) (CH2) 4-NHC CH24) 0 86 &commat; Go F3C- -NH-CH-COOC (CH3)3 H (CR2)2-C-NR2 II 0 S S s s 87 eCN2- Go H3C- 0 Oil - -0-O-CHO-C-CZH5 H C 88 QR2- Go R3C- 0 0 2 5 ,$ I-o-CH-O-C-CZHS 2
, Example R3 R2 R1 X s 1 89 ICH2)4 ((CR -N H c Acu2 sc-cEcH3)3 0 II -T,c-olcH,-o-c-e (CHJ) (L) 2 3 3 H 0 0 B 151H2C- H3C- n Il II -N C sCH sC-C2H5 H; H CR The R1 protecting groups in Examples 74, 76 and 77, the F3 protecting groups in Examples 78 and 80, and the Rg protecting groups in Examples 81 and 83 to 85 are removed as the last step in the synthesis. The R6 ester groups shown in Examples 87 to 90 are not removed.
EXAMPLE 91 ()-1-[N-[3-(Benzoylamino)-2-oxo-4-phenylbutyl]-N-methylglycyl]-L-proline, m on oh ydrochloride a) [3-(Benzoylamino)-2-oxo-4-phenylbutyl]methylcarbamic acid, phenylmethyl ester N-methyl-N-[(phenylmethoxy)carbonyl]glycine (2.23 g., 10 mmole) is dissolved in 30 ml. of tetrahydrofuran and cooled in an ice-bath. Oxalyl chloride (1 ml., 11.5 mmole) is added followed by 2 drops of dimethylformamide. After stirring for 30 minutes in the ice-bath, the mixture is then stirred at room temperature for an hour. To this 0.25 ml. of oxalyl chloride is added. The mixture is evaporated, redissolved in 15 ml. of tetrahydrofuran, and stirred in an ice bath.A solution of 2-phenyl-4-(phenylmethyl)-5(4H)oxazolone (3.1 g., 12.4 mmole) dissolved in 15 ml. of tetrahydrofuran is added to the above solution stirring in the ice-bath. Triethylamine (1.4 ml., 10 mmole) is added and the solution is stirred at room temperature overnight. The precipitated triethylamine hydrochloride salt is filtered off. Tetrahydrofuran is removed from the residue and it is then redissolved in pyridine (5 ml.) and p-dimethylamino pyridine (20 mg.) is added.
After stirring at room temperature for 3 hours, acetic acid (5 ml.) is added and the reaction mixture is kept at 105 for 30 minutes. The reaction mixture is then evaporated, the residue is dissolved in ethyl acetate, and washed with aqueous sodium bicarbonate and water. Aftertrituration with ethyl acetate/hexane, 2.2 g. of homogeneous [3-(benzoylamino)-2-oxo-4-phenylbutyl]methylcarbamic acid, phenylmethyl ester is obtained; m.p. 140-141 .
b) (+)-N-[3-(Methylamino)-2-oxo-1-(phenylmethyl)-propyl]benzamide, hydrochloride [3-(Benzoylamino)-2-oxo-4-phenylbutyl]methylcarbamic acid, phenylmethyl ester (0.5 g.) is dissolved in ethanol (50 ml.) containing 1 N hydrochloric acid (2 ml.). Palladium carbon catalyst (10%,100 mg.) is added and hydrogenation is continued overnight. The reaction mixture is then filtered, evaporated, dissolved in water, and lyophilized to 300 mg. of (+)-N-[3-(methylamino)-2-oxo-1-(phenylmethyl)propyl]benzamide, hydrochloride as a homogeneous white powder.
c) ()-1-[N-[3-(Benzoylamino)-2-oxo-4-phenylbutyl]-N-methylglycyl]-L-proline, 1, l-dimethylethyl ester A reaction mixture of ( + )-N-[3-(methylamino)-2-oxo-1 -(phenylmethyl)propyl] benzamide, hydrochloride (1.65 g., 5 mmole), 1-(bromoacetyl)-L-proline, 1,1-dimethylethyl ester (2.9 g., 10 mmole), from Example 68(a), and diisopropylethylamine (1.74 ml., 10 mmole) in dimethylformamide (20 ml.), is stirred at room temperature under nitrogen overnight. The reaction mixture is partitioned between water/ethyl acetate and the aqueous layer is extracted once more with ethyl acetate. The ethyl acetate extracts are dried (Na2SO4) and concentrated to a yellow oily residue (4.0 g.).Flash chromatography (150 g. of Merck silica gel 60) affords 0.7 g. of ()-1-[N-[3-(benzoylamino)-2-oxo-4-phenylbutyl]-N-methylglycyl]-L-proline,1,1- dimethylethyl ester as a yellow foam.
d) ()-1-[N-[3-(Benzoylamino)-2-oxo-4-phenylbutyl]-N-methylglycyl]-L-proline, monohydrochloride The ester product from part (c) (0.4 g., 0.79 mmole) is treated with 2N hydrochloric acid/acetic acid (5 ml.).
After stirring for 45 minutes at room temperature, the reaction mixture is concentrated under reduced pressure and the resulting oily residue is triturated with ether (3x) to give 0.28 g. of (i)-1 -[N-[3- (benzoylamino)-2-oxo-4-phenylbutyl]-N-methylglycyl]-L-proline, monohydrochloride as a white solid; m.p.
125-130". Ff0.73 (silica gel, n-butanol/acetic acid/water; 3:1:1).
Anal. calc'd. for C25H29N305 HCl.0.23 H2O: C, 61.01; H, 6.24; N, 8.54 Found: C,61.01; H,6.10; N,8.36.
EXAMPLE 92 (S)-7-[[[3-(Benzoylamino)-2-oxo-4-phenylbutyl]-methylamino]acetyl]- 1,4-dithia-7-azaspiro[4.4]-nonane-8- carboxylic acid, trifluoroacetate salt (1:1) a) (S)- 7- (Bromoacetyl)- 1,4-dithia-7-azaspiro-[4.4]nonane-8-carboxylic acid (S)-1,4-Dithia-7-azaspiro[4.4]nonane-8-carboxylic acid, hydrochloride (2.1 g., 8.7 mmole) is dissolved in 1 N sodium hydroxide (25 ml.), chilled to 0 and bromoacetyl bromide (2.1 g., 0.91 ml., 10.4 mmole) is added dropwise over a 10 minute period. The reaction mixture is stirred for 2 hours (0 to room temperature), washed with ethyl acetate (twice), and the aqueous layer is acidified to pH 2 and extracted with ethyl acetate (3 x).The combined organic extracts are dried (Na2SO4) and concentrated to give 2.25 g. of (S)-7 (bromoacetyl)-l ,4-dithia-7-azaspiro[4.4]nonane-8-carbox acid.
b) (S)-7-(Bromoacetyl)- 1,4-dithia-7-azaspiro[4.4]-nonane-8-carboxylic acid, diphenylmethyl ester (S)-7-(Bromoacetyl)-1,4-dithia-7-azaspiro-[4.4]nonane-8-carboxylic acid (2.25g., 6.9 mmole) is dissolved in ethyl acetate (150 ml.). Diphenyldiazomethane (1.3 g., 6.9 mmole) is added and the reaction mixture is stirred overnight at room temperature. The decolorized reaction mixture is washed with saturated sodium bicarbonate (twice), 10% potassium bisulfate (twice) and water, dried (Na2SO4), and concentrated to give 2.5 g. of (S)-7-(bromoacetyl)-1,4-dithia-7-azaspiro[4.4]nonane-8-carboxylic acid, diphenylmethyl ester as a white solid residue.
c) (S)-7-[[[3-(Benzoylamino)-2-oxo-4-phenylbutyl]-methylamino]acetyl]-1,4-dithia-7-azaspiro[4.4]nonane-8- carboxylic acid, diphenylmethyl ester A mixture of the ester product from part (b) (2.4 g., 4.87 mmole) (+)-N-[3-(methylamino)-2-oxo-1- (phenylmethyl)propyl]benzamide (0.81 g.. 2.43 mmole), prepared as set forth in Example 91(b), and diisopropylethylamine (0.85 ml., 4.87 mmole) in dimethylformamide (20 ml.) is stirred at room temperature overnight. The reaction mixture is poured into water (50 ml.), and extracted with ethyl acetate (3 x 100 ml.).
The combined organic extracts are washed with saturated sodium bicarbonate, 10% potassium bisulfate, and water, dried (Na2SO4), and concentrated into a dark oily residue (2.8 g.). Flash chromatography (200 g.
Merck silica gel, 10% ethyl acetate/methylene chloride, 20% methanol/ethyl acetate) affords 1.1 g. of (S)-7-[[[3-(benzoylamino)-2-oxo-4-phenylbutyl]-methylaminojacetyl]-1 ,4-dithia-7-azaspiro[4.4J-nonane-8- carboxylic acid, diphenylmethyl ester as a yellow oil.
d) (S)-7-[[[3-(Benzoylamino)-2-oxo-4-phenylbutyl]-methylamino]acetyl]-1,4-dithia-7-azaspiro[4,4]nonane-8- carboxylic acid, trifluoroacetate salt (1:1) The ester product from part (c) (10.5 g., 0.72 mmole) is added to chilled (OF) trifluoroacetic acid (2 ml.) containing anisole (0.1 ml.). After stirring for one hour, the volatiles are removed in vacuo and the residue is chased with toluene (twice). The oily residue is triturated with ether (4x) affording 0.36 g of (S)-7-[[[3-(benzoylamino)-2-oxo-4-phenylbutyl]methylamino]acetyl]-1 ,4-dithia-7-azaspiro[4.4]nonane-8carboxylic acid, trifluoroacetate salt (1 :1); m.p.120-125 . Rf 0.45 (trailing) (silica gel, n-butanol/acetic acid/water; 4:1:1).
Anal. calc'd. for C27H31 N305S2 C2HF302: C, 53.11; H, 4.92; N, 6.40; S, 9.78 Found: C, 52.68; H, 5.03; N, 653; S, 9.97.
EXAMPLE 93 (S)-2-[[[3-(Benzoylamino)-2-oxo-4-phen vlbutv/]methvlamino]acetv/j- 1,2,3,4-tetrahydro-3-isoquinoline- carboxylic acid, monohydrochloride a) 2-{Bromoacetyl)- 1,2,3,4-tetrahydro-3-isoquinolinecarboxylic acid, 1, 1-dimethylethyl ester To a chilled solution of 1,2,3,4-tetrahydro-3-isoquinolinecarboxylic acid, 1,1-dimethylethyl ester (7.7 g., 33 mmole) in methylene chloride (100 ml.) is added diisopropylethylamine (6.23 ml., 36.3 mmole) and finally over a 15 minute period bromoacetyl bromide (6.6 g., 2.87 ml., 33 mmole) while keeping the temperature at 5 . The reaction mixture is stirred overnight (-5 to room temperature), Concentrated to about 33 1/3% of its volume, diluted with ethyl acetate (100 ml.), washed with saturated sodium bicarbonate (twice), 10% potassium bisulfate (twice), and water (twice), dried (Na2SO4), and concentrated into a dark yellow semi-solid residue (11.0 g.). Recrystallization from ethyl acetate/hexane affords 4.2 g. of 2-(bromoacetyl)1,2,3,4-tetrahydro-3-isoquino-linecarboxylic acid, 1,1-dimethylethyl ester as a cream colored solid; m.p.
92-95' (85').
b) (S)-2-[[[3-(Benzoylamino)-2-oxo-4-phenylbutyl]-methylamino]acetyl]-1,2,3,4-tetrahydro-3-iso- quinolinecarboxylic acid, 1,1-dimethylethylester To a solution of 2-(bromoacetyl)-1,2,3,4-tetrahydro-3-isoquinolinecarboxylic acid,1,1-dimethylethyl ester (2.12 g., 6 mmole) in dimethylformamide (20 ml.) is added (~)-N-[3-(methylamino)-2-oxo-1- (phenylmethyl)propyl]benzamide (2.0 g., 6 mmole), prepared as set forth in Example 91(b), and diisopropylethylamine (0.77 g., 1.04 ml., 6 mmole). The reaction mixture is stirred overnight, poured into water (50 ml.) and extracted with ethyl acetate (3 x 50 ml.). The combined ethyl acetate extracts are washed with saturated sodium bicarbonate (twice) and water (twice), dried (Na2SO4), and concentrated into a yellow oily residue (2.9 g.). Flash chromatography (200 g.Merck silica, 2% methanol/chloroform) gives 0.68 g. of (S)-2-[[[3-(benzoylamino)-2-oxo-4-phenylbutyljmethylaminojacetyli-1 ,2,3,4-tetrahydro-3- isoquinolinecarboxylic acid,1,1-dimethylethyl ester as a yellow dried up foam.
c) (S)-2-[[[3-(Benzoylamino)-2-oxo-4-phenylbutyl]methylamino]acetyl]-1,2,3,4-tetrahydro-3- isoquinolinecarboxylic acid, monohydrochloride The ester product from part (b) (1.67 g., 1.17 mmole) is treated with 2N hydrochloric acid/acetic acid (5 ml.).
After stirring for one hour at room temperature, the reaction mixture is concentrated under reduced pressure and the resulting oily residue is triturated with ether (4x) to give 0.55 g. of (S)-2-[[[3-(benzoylamino)-2-oxo-4- phenylbutyl]methylamino]acetyl]-1,2,3,4-tetrahydro-3-isoquinolinecarboxylic acid, monohydrochloride as an off white solid; m.p. 123-126 . Rf 0.47 (silica gel, n-butanol/acetic acid/water; 4:1 :1).
Anal. calc'd. for C30H31N3O5 HCl 0.32 H2O: C, 64.82; H, 5.92; N, 7.56; Cl, 6.38 Found: C, 64.82; H, 6.22; N, 7.55; Cl,6.13 EXAMPLE 94 [1(t), 4Sj- 1-[N-[3-(Benzoylamino)-2-oxo-4-phenylbutyl]-N-methylglycyl]-4-(phenylthio)-L-proline, monohydrochloride a) (4S)-1-(Bromoacetyl)-4-(phenylthio)-L-proline To a suspension of (4S)-4-(phenylthio)-L-proline (2.2 g., 10 mmole) in methylene chloride (50 ml., freshly distilled) is added bis(trimethylsilyl) acetamide (7.35 ml., 30 mmole). The reaction mixture is stirred at room temperature for 2 hours until it becomes almost clear.The reaction mixture is then cooled to -Sand bromoacetyl chloride (1.9 g., 1.0 ml., 12 mmole) is added dropwise keeping the temperature at -5 . After stirring overnight (- 5 to room temperature), the reaction mixture is concentrated to about 50% of its volume, partitioned between saturated sodium bicarbonate/ethyl acetate and the layers are separated. The organic layer is extracted once more with saturated sodium bicarbonate. The combined aqueous layers are acidified to pH 2.0 with 10% potassium bisulfate and extracted with ethyl acetate (3x). The ethyl acetate fractions are combined, dried (Na2SO4) and concentrated to give 3.5 g. of (4S)-1-(bromoacetyl)-4- (phenylthio)-L-proline as a viscous oil.
b) (45)- 1-(Bromoacetyl)-4-(phenylthio)-L-proline, diphenylmethyl ester A solution of diphenyldiazomethane (2.0 g., 10.2 mmole) in ethyl acetate (50 ml.) is added dropwise to a solution of (4S)-1-(bromoacetate)-4-(phenylthio)-L-proline (3.5 g., 10.2 mmole) in ethyl acetate (50 ml.). The purple solution is stirred at room temperature overnight. The decolorized reaction mixture is washed with saturated sodium carbonate (twice) and water (twice), dried (Na2SO4), and concentrated to give 4.78 g. of (4S)-1-(bromoacetyl)-4-(phenylthio)-L-proline, diphenylmethyl ester as a yellow viscous oil.
c) [1(),4S]-1-[N-[3-(Benzoylamino)-2-oxo-4-phenylbutyl]-N-methylglycyl]-4-(phenylthio)-L-proline, diphenylmethyl ester To a solution of (4S)-1-(bromoacetyl)-4-(phenylthio)-L-proline, diphenylmethyl ester (4.78 g., 9.4 mmole) in dimethylformamide (20 ml.) is added (+)-N-[3-(methylamino)-2-oxo-1-(phenylmethyi)propyl]benzamide (2.42 g., 7.2 mmole), prepared as set forth in Example 91(b), and diisopropylethylamine (0.93 g.,1.25 ml.,7.2 mmole). After stirring overnight at room temperature, the reaction mixture is poured into water (50 ml.) and extracted with ethyl acetate (3x). The combined ethyl acetate extracts are washed with saturated sodium bicarbonate (twice) and water (twice), dried (Na2SO4), and concentrated into a yellow oil (6.2 g.).Flash chromatography (Merck silica gel, 2% methanol/methylene chloride) gives 3.2 g. of [1(),4S]-1-[N-[3- (Benzoylamino)-2-oxo-4-phenylbutyl]-N-methylglycyl]-4-(phenylthio)-L-proline, diphenylmethyl ester as a pale yellow foam.
d) II (t),45J- 1-[N-[3-(Benzoylamino)-2-oxo-4-phenylbutyl]-N-methylglycyl]-4-(phenylthio)-L-proline, monohydrochloride The ester product from part (c) (1.6 g., 2.2 mmole) is treated with 2N hydrochloric acid/acetic acid (20 ml).
After stirring for 2 hours at room temperature, the reaction mixture is concentrated under reduced pressure and the oily residue is triturated with ether overnight to yield 1.2 g. of [1(),4S]-1-[N-[3-(benzoylamino)-2- oxo-4-phenylbutyl]-N-methylglycyl]-4-(phenylthio)-L-proline, monohydrochloride as an off-white solid; m.p.
131-133 Rf 0.38 (silica gel, n-butanol/acetic acid/water; 4:1 :1).
Anal. calc'd. foTC31H33N305S . HCl 0.9H2O: C, 60.82; H, 5.90; N, 6.87; S, 5.24; Cl, 5.79 Found: C, 60.82; H, 5.74; N, 6.94; S, 5.25; Cl, 5.75.
EXAMPLE 95 (45)- 1-[N-[3-(Benzoylamino)-2-oxo-4-phenylbutyl]-N-methylglycyl]-4-(4-fluorophenoxy)-L-proline, mono- hydrochloride a) {4S)- 1-(Bromoacetyl)-4-(fluorophenoxy)-L-proline, 1, 1-dimethylethyl ester To a solution of (S)-4-(fluorophenoxy)-L-proline, 1,1-dimethylethyl ester (2.1 g., 7.5 mmole in distilled tetrahydrofuran (50 ml.) is added bromoacetic acid (1.04 g., 7.5 mmole), hydroxybenzotriazole hydrate (1.14 g., 7.5 mmole) and dicyclohexylcarbodiimide (1.54 g., 7.5 mmole). The reaction mixture is stirred overnight, the precipitated dicyclohexylurea is filtered off, and the filtrate is concentrated.The residue is dissolved in ethyl acetate (50 ml.) and washed with saturated sodium bicarbonate (twice), 10% potassium bisulfate (twice) and water (twice), dried (Na2SO4) and concentrated to give 3.1 g. of (4S)-1-(bromoacetyl)-4 (fluorophenoxy)-L-proline, 1,1-dimethylethyl ester as an oily residue.
b) (4S)-i -[N-[3-(Benzo vlamin o)-2-oxo -4-ph en ylb utyl]-N-meth vlg/ycylj-4-(4-fluoroph en oxy)-L-prolln e, 1,1dimethylethyl ester To a solution of (4S)-1-(bromoacetyl)-4-(fluorophenoxy)-L-proline,1,1-dimethylethyl ester (3.4 g., 8.5 mmole) in dimethylformamide (20 ml.) is added ()-N-[3-(methylamino)-2-oxo-1-(phenylmethyl)- propyl]benzamide (2.83g.,8.5 mmole), prepared as set forth in Example 91(b), and diisopropylethylamine (1.43 g., 1.92 ml., 11.0 mmole). After stirring overnight at room temperature, the reaction mixture is poured into water (100 ml.) and extracted with ethyl acetate (3x).The combined ethyl acetate extracts are washed with saturated sodium bicarbonate (twice), 10% potassium bisulfate (twice), and water (twice), dried (Na2SO4), and concentrated into a dark residue (5.5 g.). Flash chromatography (LPS-1 silica gel, 50% ethyl acetate/methylene chloride) gives 1.2 g. of (4S)-1-[N-[3-(benzoylamino)-2-oxo-4-phenylbutyl]-N- methylglycyl]-4-(4-fluorophenoxy)-L-proline,1,1-dimethylethyl ester as a pale yellow foam.
c) (45)- 1-[N-[3-(Benzoylamino)-2-oxo-4-phenylbutyl]-N-methylglycyl]-4-(4-fluorophenoxy)-L-proline, monohydrochloride The ester product from part (b) (1.2 g., 1.95 mmole) is treated with 2N hydrochloric acid/acetic acid (20 ml.).
After stirring for 2 hours at room temperature, the reaction mixture is concentrated under reduced pressure and the oily residue is triturated with ether overnight to yield 0.92 g. of (4S)-1-[N-[3-(benzoylamino)-2-oxo-4phenylbutyl]-N-methylglycyl]-4-(4-fluorophenoxy)-L-proline, monohydrochloride as an off-white solid; m.p.
131-140 . Rf 0.54 (silica gel, n-butanol/acetic acid/water; 3:1:1).
Anal. calc'd. for C31H32N3FO8 .HCl. 0.55 H20: C, 61.24; H, 5.65; N, 6.91; Cl, 5.83 Found: C, 61.24; H, 5.66; N, 7.09; Cl, 5.70.
In a similar manner, the procedure of Examples 91 to 95 can be employed to prepare the compounds of Examples 1 to 90.
EXAMPLE 96 N-[N-[3-(Benzoylamino)-2-oxo-4-phenylbutyl]-N-methylglycyl)-N-cyclohexylglycine, monohydrochloride a) {+)-N-[3-{Benzoylamino)-2-oxo-4-phenylbutyl7-N-methylglycine, 1, I-dimethylethyl ester To a solution of (+)-N-[3-(methylamino)-2-oxo-1-(phenylmethyl)propyl]benzamide (5.0 g., 15 mmole), prepared as set forth in Example 91(b), in dimethylformamide (20 ml.) is added bromoacetic acid, 1,1-dimethylethyl ester (13.8 g., 3.15 ml., 19.5 mmole) and diisopropylethylamine (2.5 g., 3.4 ml., 19.5 mmole). After stirring overnight at room temperature, the reaction mixture is poured into water (100 ml.) and extracted with ethyl acetate (3x).The combined ethyl acetate exytracts are washed with saturated sodium bicarbonate (twice), 10% potassium bisulfate (twice), and water (twice), dried (Na2SO4), and concentrated into a yellow oil, which becomes a dried up foam upon drying in high vacuum, to give 5.4 g. of ()-N-[3-(benzoylamino)-2-oxo-4-phenylbutyl]-N-methylglycine,1,1-dimethylethyl ester.
b) ()-N-[3-(Benzoylamino)-2-oxo-4-phenylbutyl]-N-methylglycine, monohydrochloride The ester product from part (a) (4.51 g., 11 mmole) is treated with 2N hydrochloric acid/acetic acid (20 ml.).
After stirring for 2.5 hours at room temperature, the reaction mixture is concentrated under reduced pressure and the oily residue is triturated with ether to give 3.3 g. of (+)-N-[3-(benzoylamino)-2-oxo-4- phenylbutylj-N-methylglycine, monohydrochloride as an off-white solid.
c) N-[N-[3-(Benzoylamino)-2-oxo-4-phenylbutyl]-N-methylglycyl]-N-cyclohexylglycine, 1, I-dimethylethyl ester To a solution of )-N-[3-(benzoylam ino)-2-oxo-4-phenylbutyl]-N-methylg lycine, hydrochloride (1.0 g., 2.6 mole) in distilled tetrahydrofuran (50 ml.) is added N-cyclohexylglycine, 1,1-dimethylethyl ester (0.55 g., 2.6 mmole), prepared as set forth in example 65(a), hydroxybenzotriazole hydrate (0.39 g., 2.6 mmole), and dicyclohexylcarbodiimide (0.55 g., 2.6 mmole). The reaction mixture is stirred overnight, the precipitated dicyclohexylurea is filtered off, and the filtrate is concentrated.The residue is dissolved in ethyl acetate (50 ml.) and washed with saturated sodium bicarbonate (twice), 10% potassium bisulfate (twice), and water (twice), dried (Na2SO4) and concentrated into an oily residue (1.5 g.). Flash chromatography )100 g., Merck silica gel 60) gives 0.49 g. of N-[N-[3-(benzoylamino)-2-oxo-4-phenylbutyl]-N-methylglycyl]-N- cyclohexylglycine, 1,1 -dimethylethyl ester as a foam.
d) N-[N-[3-(Benzoylamino)-2-oxo-4-phenylbutyl]-N-methylglycyl]-N-cyclohexylglycine, monohydrochloride The ester product from part (c) (0.48 g., 0.87 mmole) is treated with 2N hydrochloric acid/acetic acid (10 ml.). After stirring for 2 hours at room temperature, the reaction mixture is concentrated under reduced pressure and the oily residue is triturated with ether overnight to give 0.32 g. of N-[N-[3-(benzoylamino)-2 oXo-4-phenylbutyl]-N-methylglycyl]-N-cyclohexylglycine, monohydrochloride as an off-white solid; m.p.
131-145 . Rf 0.36 (silica gel, n-butanol/acetic acid/water; 4:1:1).
Anal. calc'd. forC28H35N3O5 HCl 0.7 H2O: C, 61.95; H, 6.95; N, 7.74; Cl, 6.53 Found: C, 61.95; H, 6.74; N, 7.71; Cl, 6.23.
EXAMPLE 97 (S)-7-[[[()-3-(Benzoylamino)-2-oxo-4-phenylbutyl]-methylamino]acetyl]- 1,4-dithia-7-azaspiro[4.4]-nonane- 8-carboxylic acid, methyl ester To a solution of ()-N-[3-(benzoylamino)-2-oxo-4-phenylbutyl]-N-methylglycine, monohydrochloride (1.0 g., 2.5 mmole), prepared as set forth in Example 96(b), in distilled tetrahydrofuran (50 ml.) is added (S)-1,4-dithia-7-azaspiro[4.4]nonane-8-carboxylic acid, methyl ester, monohydrochloride (0.66 g., 2.5 mmole), dicyclohexylcarbodiimide (0.54 g., 2.5 mmole), hydroxybenzotriazole hydrate (0.39 g., 2.5 mmole) and diisopropylethylamine (0.9 ml., 5 mmole). The reaction mixture is stirred overnight, the precipitated dicyclohexylurea is filtered off, and the filtrate is concentrated.The residue is dissolved in ethyl acetate (100 ml.) and washed with saturated sodium bicarbonate (twice) and water (twice), dried (Na2SO4), and concentrated into a yellow oily residue (1.3 g.). Flash chromatography (Merck silica gel, 25% ethyl acetate/methylene chloride, 1% methanol/methylene chloride) affords 0.53 g. of (S)-7-[[[(+)-3- (benzoylamino)-2-oxo-4-phenylbutyl]methylamino]-acetyl]-1,4-dithia-7-azaspiro[4.4]nonane-8-carboxylic acid, methyl ester as a white foam; m.p. 60 - 62 . Rf 0.52 (silica gel,5% methanol/methyene chloride).
Anal. calc'd. for c28H33N305S2 . 0.33 H2O: C,59.87; H,6.04; N,7.48; S,11.42 Found: C,59.87; H, 5.94; N,7.56; S,11.36.
EXAMPLE 98 (S)-7-[[[()-3-(Benzoylamino)-2-oxo-4-phenylbutyl]-methylamino]acetyl]-1,4-dithia-7-azaspiro[4.4)nonane-8- carboxylic acid, methyl ester, monohydrochloride The methyl ester product from Example 97 (0.26 g., 0.46 mmole) is treated with 2N hydrochloric acid/acetic acid until homogeneous (2minutes), concentrated under reduced pressure, and the oily residue is triturated with ether (twice) to give 0.26 g. of (S)-7-[[[()-3-(benzoylamino)-2-oxo-4-phenylbutyl]methylamino]-acetyl]- 1,4-dithia-7-azaspiro[4.4]nonane-8-carboxylic acid, methyl ester, monohydrochloride as a white solid; m.p.
79-85 . Rf 0.53 (silica gel,5% methanol/methylene chloride).
Anal. calc'd. for C28H33N3O5S2 HCl 0.56 H2O: C, 55.84; H, 5.88; N, 6.98; S, 10.64; Cl, 5.88 Found: C, 55.84; H, 5.95; N, 6.78; S, 10.43; Cl, 5.66.
EXAMPLE 99 (4S)-1-[N-[3-(Benzoylamino)-2-oxo-4-phenylbutyl]-N-methylglycyl]-4-(4-fluorophenoxy)-L-proline, methyl ester, monohydrochloride a) (4S)-4-(Fluorophenoxy)-L-proline, methyl ester, monohydrochloride To a suspension of (4S)-4-(fluorophenoxy)-L-proline (2.5 g., 11 mmole) in methanol at-30 under an argon atmosphere is added thionyl chloride (8.09 ml., 11 mmole). The reaction mixture is stirred at-20 for 2 hours, then at room temperature for 16 hours. Solvent is removed at reduced pressure and the residue is redissolved in methylene chloride (150 ml.) and washed with 1 N sodium carbonate (twice) and water (twice).
After drying (MgSO4), excess hydrochloric acid/methanol is added and solvent is removed at reduced pressure. Addion of ether gives a light brown solid (2.6 g.). Recrystallization from methanol/ether gives 1.49 g. of (4S)-4-(fluorophenoxy)-L-proline, methyl ester, monohydrochloride as a light brown solid; m.p.
147-148 ; [0C]2DO = +6.96 (c = 1.55, methanol).
b) (4S)-1-[N-[3-(Benzoylamino)-2-oxo-4-phenylbutyl]-N-methylglycyl]-4-)4-fluorophenoxy)-L-proline, methyl ester To a solution of ()-N-[3-(benzoylamino)-2-oxo-4-phenylbutyl]-N-methylglycine, monohydrochloride (1.17 g., 3 mmole), prepared as set forth in Example 96(b), in distilled tetrahydrofuran (20 ml.) is added (4S)-4-(fluorophenoxy)-L-proline, methyl ester, monohydrochloride (0.82 g., 3 mmole), hydroxybenzotriazole hydrate (0.46 g., 3 mmole) and dicyclohexylcarbodiimide (0.62 g., 3 mmole). The reaction mixture is stirred overnight, the precipitated dicyclohexylurea is filtered off, and the filtrate is concentrated. The residue is dissolved in ethyl acetate (50 ml.) and washed with saturated sodium bicarbonate (twice) and water (twice), dried (Na2SO4), and concentrated into an oily residue (1.1 g.). Flash chromatograpy (200 g., Merck silica gel 60; 3% methanol/chlorofrom) gives 0.15 g. of (4S)-1-[N-[3-(benzoylamino)-2-oxo-4-phenylbutyl]-N- methylglycyl]-4-(4-fluorophenoxy)-L-proline, methyl ester as a foam.
c) (4S)-1-[N-[3-(Benzoylamino)-2-oxo-4-phenylbutyl]-N-methylglycyl]-4(4-fluorophenoxy)-2-proline, methyl ester, monohydrochloride The methyl ester product from part (b) (0.15 g., 0.26 mmole) is treated with 2N hydrochloric acid/acetic acid until homogeneous (2 minutes), concentrated under reduced pressure, and the oily residue is triturated with ether (twice) to afford 0.14 g. of (4S)-1-[N-[3-(benzoylamino)-2-oxo-4-phenylbutyl]-N-methylglycyl]-4-(4- fluorophenoxy)-L-proline, methyl ester, monohydrochloride as an off-white solid; m.p. 105-125 , Rf 0.27 (silica gel, 5% methanol/chloroform).
Anal. calc'd. for C32H34FO6 . HCl C, 62.79; H, 5.76; N, 6.86; F, 3.10; Cl, 5.79 Found: C, 62.78; H, 5.73; N, 6.87; F, 2.83; Cl, 5.33.
EXAMPLE 100 (4S)-1-[N[(S)-3-(Benzoylamino)-2-oxo-4-phenylbutyl]-L-alanyl]-4-(4-fluorophenoxy)-L-proline, monohydrochloride a) {S)-N-[3-rBenzoylamino)-2-oxo-4-phenylbutyl7-L-alanine, 1,1-dimethylethyl ester To a stirring solution of (S)-N-[3-chloro-2-oxo-1-(phenylmethyl)propyl]benzamide )10.0 g., 33.1 mmole) in dimethylformamide (80 ml.) is added L-alanine, 1,1-dimethylethyl ester, hydrochloride (6.0 g., 33.1 mmole), sodium bicarbonate )6.1 g., 72 mmole) and sodium iodide (4.9 g., 33.1 mmole). The resulting solution is stirred overnight at room temperature, poured into ether and washed with water (twice) and 10% sodium bicarbonate.The ether solution is extracted with 1 N hydrochloric acid (3x), the combined extracts are made basic by the addition of solid sodium bicarbonate and extracted with ethyl acetate (4x). The organic extracts are combined, dried (MgSO4) and concentrated to give 8.9 g. of pale yellow solid. A portion of this material is recrystallized from ethyl acetate to give (S)-N-[3- > benzoylamino)-2-oxo-4-phenylbutyl]-L-alanine,1,1- dimethylethyl ester as a white solid; m.p. 106.5- 1 10'C.
b) (S)-N-[3-(Benzovlamino)-2-oxo-4-phen vlbutylj-L-a/anine, monohydrochloride A solution of the ester product from part (a) (2.95 g., 5.4 mmole) in 1.4 N hydrochloric acid in acetic acid (39 ml.) is stirred at room temperature for 2 hours. The resulting white precipitate is collected, rinsed with ether and dried to give 2.27 g. of (S)-N-[3-(benzoylamino)-2-oxo-4-phenylbutylj-L-alanine, monohydrochloride; m.p. 208-209" (dec.); [a]D = -71" (c = 0.38% in methanol). Rf 0.51 (silica gel; chlornform/methanoVacetic acid; 4:1:1).
Anal. calc'd. for C20H22N204 . HCl: C, 61.64; H, 5.93; N, 7.17; Cl, 9.07 Found: C, 61.33; H, 5.97; N, 7.17; Cl, 8.79.
c) (S)-N-[N-(Benzoylamino)-2-oxo-4-phenylbutyl]-N-[(phenylmethoxy)carbonyl]-L-alanine Triethylamine (2.1 ml., 15 mmole) is added to a mixture of (S)-N-[3-(benzoylamino)-2-oxo-4-phenylbutyl] L-alanine, monohydrochloride (2.0 g., 5.1 mmole), benzyl chloroformate (730 pI., 5.1 mmole), water (7 ml.) and dioxane (7 ml.) at 25 . The resulting mixture is stirred at 25 for 3 hours, after which it is poured into 5% aqueous sodium bicarbonate solution and washed with ether. The aqueous layer is acidifeid (HCI) and extracted into ethyl acetate (3x). The extract is dried (MgSO4) and concentrated to give a colorless oil.
Trituration with ether produces a white granular solid (150 mg.) which is collected and discarded. The mother liquor is concentrated in vacuo to give 1.75 g. of (S)-N-[N-(benzoylamino)-2-oxo-4-phenylbutyl]-N- [(phenylmethoxy)carbonyl]-L-alanine as a white glass.
d) (4S)-1-[N-(S)-3-(Benzoylamino)-2-oxo-4-phenylbutyl]-N-[(phenylmethoxy)carbonyl]-L-alanyl]-4-(4- fluorophenoxy)-L-proline, phenylmethyl ester A mixture of (S)-N-[N-(benzoylamino)-2-oxo-4-phenylbutyl]-N-[(phenylmethoxy)carbonyl]-L-alanine (300 mg., 0.62 mmole), (4S)-4-(44luorophenoxy)-L-proline, phenylmethyl ester, p-toluenesulfonic acid salt (300 mg., 0.62 mmole), triethylamine (90 l.,0.62 mmole), dicyclohexylcarbodiimide (130 mg., 0.62 mmole), and hydroxybenzotriazole hydrate (90 mg., 0.62 mmole) in tetrahydrofuran (7 ml.) is stirred at 25 for 20 hours.
The mixture is then filtered and diluted with ethyl acetate. The resulting solution is washed sequentially with 1N hydrochloric acid and 10% aqueous sodium bicarbonate solution, dried (MgSo4), filtered, and concentrated to give 500 mg. of (4S)-1-[N-[(S)-3-(benzoylamino)-2-oxo-4-phenylbutyl]-N- [(phenylmethoxy)carbonyl]-L-alanyl]-4-(4-fluorophenoxy)-L-proline, phenylmethyl ester as a pale yellow oil.
e) (4S)-1-[N-[(S)-3-(Benzoylamino)-2-oxo-4-phenylbutyl]-L-alanyl]-4-(4-fluorophenoxy)-L-proline, monohydrochloride A mixture of the ester product from part (d) (500 mg., 0.6 mmole), palladium on carbon catalyst (10%, 100 mg.), absolute ethanol (15 ml.), and 1.0 N aqueous hydrochloric acid (800 p1.,0.8 mmole) is hydrogenated at 1 atmosphere and 25 for 17 hours, after which it is filtered and concentrated. The residue is chromatographed on HP-20 a linear gradient from [9:1,0.01 N aqueous hydrochloric acid:methanol] to [1 :1, 0.01 N aqueous hydrochloric acid:methanol]. Fractions containing the desired product (TLC) are combined and concentrated. The residue is dissolved in a minimum amount of methanol.Ether is added, resulting in a white precipitate which is collected and dried in vacuo to give 200 mg. of (4S)-1-[N-[(S)-3-(benzoylamino)-2 oxo-4-phenylbutyl]-L-alanyl]-4-(4-fluorophenoxy)-L-proline, monohydrochloride; m.p. 152-153 (dec.); [a]2J =-50 (c - 0.5, methanol). Rf 0.75 (silica gel, chloroform/methanol/acetic acid, 4:1:1).
Anal. calc'd.for C31H32FN3O6 HCl 1.5H2O: C, 59.57; H, 5.80; N, 6.72; Cl, 5.67 Found: C, 59.68; H, 5.56; N, 6.67; Cl, 5.99.
EXAMPLE 101 [1(S),4R]-1-[N-[3-(Benzoylamino)-2-oxo-4-phenylbutyl]-L-alanyl]-4-phenyl-L-proline, monohydrochloride a) (S)-N-[N-(Benzoylamino)-2-oxo-4-phenylbutyl]-N-[(phenylmethoxy)carbonyl]-L-alanine, succinimido ester A mixture of (S)-N-[N-(benzoylamino)-2-oxo-4-phenylbutyl]-N-[(phenylmethoxy)carbonyl]-L-alanine (800 mg., 1.6 mmole), prepared as set forth in Example 100 (c), dicyclohexylcarbodiimide (340 mg., 1.6 mmole), and N-hydrnxysuccinimide (190 mg., 1.6 mmole) in tetrahydrofuran (5 ml.) is stirred at 25' for 18 hours. After this time it is filtered and concentrated to give 950 mg. of (S)-N-[N-(benzoylamino)-2-oxo-4-phenylbutyl)-N- [(phenylmethoxy)carbonyl]-L-alanine, succinimido ester.
b) [1(S),4R]-1- [N-[3-Benzoylamino)-2-oxo-4-phenylbutyl]-N-[phenylmethoxy)carbonyl]-L-alanyl]-4-phenyl- L-proline To a solution of (S)-N-[N-(benzoylamino)-2-oxo-4-phenylbutyl]-N-[(phenylmethoxy)carbonyl]-L-alanine, succinimido ester (950 mg., 1.6 mmole) in dimethylformamide (5 ml.) is added (4R)-4-phenyl-L-proline, hydrochloride (375 mg., 1.7 mmole) and triethylamine (40 l., 3.2 mmole). The resulting mixture is stirred at 25 for 24 hours, after which it is poured into excess 1 N hydrochloric acid and extracted with ethyl acetate (3x). The extracts are combined, dried (MgSO4), filtered, and concentrated to give 1.1 g. of [1(S),4R]-1-[N-[3- (benzoylamino)-2-oxo-4-phenylbutyl]-N-[(phenylmethoxy)carbonyl]-L-alanyl)-4-phenyl-L-proline.
c) [1(S),4R]-1-[N-[3-(Benzoylamino)-2-oxo-4-phenylbutyl]-L-alanyl]-4-phenyl-L-proline, monohydrochloride The product from part (b) (1.0 g., 1.5 mmole), ethanol (20 ml.), water (5 ml.), 1.0 N hydrochloric acid (1.5 ml., 1.5 mmole), and palladium on carbon catalyst (10%, 100 mg.) is hydrogenated at one atmosphere and 25 for 18 hours, after which it is filtered and concentrated. The residue is chromatographed on HP-20 using a linear gradient [0.01 N aqueous hydrochloric acid:methanol, 40:60 to 10:90]. Fractions containing the desired product (TLC) are combined and concentrated. The residue is dissolved in a minimum amount of methanol.Ether is added and the resulting white precipitate is collected and dried to give 300 mg. of [1 (S),4F]-1 -[N-[3-(benzoylamino)-2-oxo-4-phenylbutyl]-L-alanyl]-4-phenyl-L-proline, monohydrochloride; m.p. 160-162 (dec.); [&alpha;]D25 = -57 (c = 1.5, methanol). Rf 0.8 (silica gel; chloroform/methanol/acetic acid; 4:1:1).
Anal. calc'd. for C31H33N3O5 . HCl . 1.35H2O: C, 63.27; H, 6.29; N, 7.14; Cl, 6.02 Found: C, 63.27; H, 6.17; N, 7.19; Cl, 5.97.
EXAMPLE 102 [1(S),4S]-1-[N-[3-(Benzoylamino)-2-oxo-4-phenylbutyl]-L-alanyl]-4-phenyl-L-proline, monohydrochloride Following the procedure of Example 101 but employing (4S)-4-phenyl-L-proline, hydrochloride in part (b), one obtains [1 (S),4S]-1 -[N-[3-(benzoylamino)-2-oxo-4-phenylbutyl]-L-alanyl-4-phenyl-L-proline, monohydrochloride; m.p. 138-143 ; [alo = -61 (c = 0.3% in methanol). Rf 0.84 (silica gel, chloroform/methanoll acetic acid, 4:1:1).
Anal. calc'd.forC31H33N3O8 . HCl . 2.13 H2O: C, 61.80; H, 6.35; N, 6.98; Cl, 5.88 Found: C, 61.80; H, 6.06; N, 7.05; Cl, 5.65.
EXAMPLE 103 [1(S),4R]-1-[N-[3-(Benzoylamino)-2-oxo-4-phenylbutyl-L-alanyl]-4-cyclohexyl-L-proline, monohydrochloride Following the procedure of Example 101 but employing (4R)-4-cyclohexyl-L-proline, hydrochloride inpart (b), one obtains [1(S),4R]-1-[N-[3-(benzoylamino-2-oxo-4-phenylbutyl]-L-alanyl]-4-cyclohexyl-L-proline, monohydrochloride; m.p. 140-154 (dec.); [&alpha;]D = -83 (c = 0.36% in methanol). Rf 0.84 (silica gel; chloroform/methanol/acetic acid; 4:1:1).
Anal. calc'd. for C31H39N305 . HCl . 0.79 H2O: C, 63.71; H, 7.17; N, 7.19; Cl, 6.06 Found: C, 63.71; H, 7.21; N, 7.05; Cl, 5.82.
EXAMPLE 104 [1(S),4S]-1-[N-[3-(Benzoylamino)-2-oxo-4-phenylbutyl]-L-alanyl]-4-cyclohexyl-L-proline, monohydrochloride Following the procedure of Example 101 but employing (4S)-4-cyclohexyl-L-proline, hydrochloride in part (b), one obtains [1 (S),4S]-1 -[N-[3-(benzoylamino)-2-oxo-4-phenylbutyl]-L-alanyl]-4-cyclohexyl-L-proline, monohydrochloride; m.p. 139-141 (dec.); [a[o = -80 (c = 0.2% in methanol). Rf 0.83 (silica gel; chloroform/methanol/acetic acid; 4:1:1).
Anal. calc'd. for C31H38N3O5 HCl 1.54 H2O: C, 62.28; H, 7.26; N, 7.03; Cl, 5.93 Found: C, 62.28; H, 7.01; N, 7.02; Cl, 6.16.
EXAMPLE 105 (S)-7-[(S)-2-[[3-(Benzoylamino)-2-oxo-4-phenylbutyl]-amino]-1-oxopropyl]-1,4-dithia-7-azaspiro[4.4]nonane- 8-carboxylic acid, monohydrochloride Following the procedure of Example 101 but employing (S)-1,4-dithia-7-azaspiro[4.4] nonane-8-carboxylic acid, hydrochloride in part (b) for the L-proline reactant, one obtains (S)-7-[(S)-2-[[3-(benzoylamino)-2-oxo-4- phenylbutyl]amino]-1-oxopropyl]-1,4-dithia-7-azaspiro[4.4]nonane-8-carboxylic acid, monohydrochloride; m.p. 170-172'; [(X]25 = - 26 (c = 1.4% in methanol). Rf0.78 (silica gel; chlorofom/methanol/acetic acid: 6:1:1).
Anal. calc'd. for C27H31N305S2 . HCl . 0.77 H2O: C, 54.77; H, 5.71; N, 7.10; S, 10.83; Cl, 5.99 Found: C, 54.77; H, 5.70; N, 6.94; S, 10.82; Cl, 6.07.
EXAMPLE 106 [1(S), 5S]- 1-[N-[3-(Benzoylamino)-2-oxo-4-phenylbutyl]-L-alanyl]-4,5-dihydro-3-phenyl-1H-pyrazole-5- carboxylic acid, monohydrochloride Following the procedure of Example 101 but employing (S)-4-,5-dihydro-3-phenyl-1 H-pyrazole-5carboxylic acid for the L-proline reactant in part (b), one obtains the above named compound.
EXAMPLE 107 tS)-2-[N-[(5)-3-(BenzoYlamino)-2-oxo-4-phenylbutyly-L-alanyly- 1,2,3,4-tetrahydro-3-isoquinolinecarboxylic acid, monohydrochloride Following the procedure of Example 101 but employing (S)-1,2,3,4-tetrahydro-3-isoquinolinecarboxylic acid, hydrochloride in part (b) in place of the proline reactant, one obtains (S)-2-[N-[(S)-3-(benzoylamino)-2oxo-4-phenylbutyl]-L-alanyl]-1,2,3,4-tetrahydro-3-isoquinolinecarboxylic acid, monohydrochloride.
EXAMPLE 108 1-[N-[(S)-3-(Benzoylamino)-2-oxo-4-phenylbutyl]-L-alanyl]-2-(2-hydroxyphenyl)-4(R)-thiazolidinecarboxylic acid, monohydrochloride Following the procedure of Example 101 but employing 2-[(2-phenylmethoxy)phenyl]-4(R)thiazolidinecarboxylic acid, hydrochloride in part (b) in place of the proline reactant, one obtains after removal of the hydroxy protecting group 1-[N-[(S)-3-(benzoylamino)-2-oxo-4-phenylbutyl]-L-alanyl]-2-(2- hydroxyphenyl)-4(R)-thiazolidinecarboxylic acid, monohydrochloride.
In a similar manner, the processes of Examples 96, 97,99 and 100 to 108 can be employed to prepare the compounds of Examples 1 to 95.
EXAMPLE 109 ()-1-[N-[3-(Benzoylamino)-2-oxo-4-phenylbutyl]-L-alanyl]-L-proline, methyl ester, monohydrochloride a) 1-[N-(2-Ethoxy-2-oxoethyl)-N-[(phenylmethoxy)-carbonyl]-L-alanyl]-L-proline, 1, 1-dimethylethyl ester L-Alanyl-L-proline,1,1-dimethylethyl ester (25.44 9.,105 mmole) is taken into tetrahydrofuran (400 ml.) with stirring. To this bromoethyl acetate (11.64 ml., 105 mmole) and diisopropylethylamine (18.3 ml., 105 mmole) are added. After 6 hours the reaction mixture is chilled in an ice bath and benzyl chloroformate (16.5 ml., 115.5 mmole) and diisopropylethylamine (20.1 ml., 115.5 mmole) are added. After hour the ice-bath is removed and the reaction mixture is kept overnight at room temperature.It is then concentrated to dryness, taken into ethyl acetate, and washed neutral with 10% potassium bisulfate and saturated sodium bicarbonate. The crude product (52.3 g.) is purified on a silica gel column eluting with ethyl acetate:hexane (1:1) to yield 42.4 g. of 1-[N-(2-ethoxy-2-oxoethyl)-N-[(phenylmethoxy) carbonyl]-L-alanyl]-L-proline, 1,1- dimethylethyl ester.
b) 1-[N-(Carboxymethyl)-N-[(phenylmethoxy)carbonyl]-L-alanyl]-L-proline, 1,1-dimethylethyl ester The ester product from part (a) (21 g., 45.4 mmole) is taken into methanol (150 ml.) and 1 N sodium hydroxide (50 ml., 50 mmole) with stirring at room temperature. After 5.5 hours the methanol is removed in vacuo and the aqueous portion is extracted with ethyl acetate. The aqueous portion is acidified with concentrated hydrochloric acid and extracted into ethyl acetate to yield 16.95 g. of 1 -[N-(carboxymethyl)-N [(phenylmethoxy)carbonyl]-L-alanyl]-L-proline,1,1-dimethylethyl ester.
c)()-1-[N-[N-[3(Benzoylamino)-2-oxo-4-phenylbutyl]-N-[(phenylmethoxy)carbonyl]-L-alanyl]-L-proline, 1,1dimethylethyl ester The ester product from part (b) (10.0 g., 23 mmole) is taken into dry tetrahydrofuran (75 ml.) with stirring in an ice-bath. To this, oxalylchloride (2.4 ml., 27.6 mmole) is added dropwise followed by 15 drops of dimethylformamide. After 20 minutes the ice-bath is removed and the reaction mixture is kept at room temperature for one hour. The mixture is then concentrated to dryness in vacuo and taken into tetrahydrofuran (40 ml.) with stirring in an ice-bath. To this, 2-phenyl-4-(phenylmethyl)-5(4H)-oxazolone (6 g., 23.8 mmole) in tetrahydrofuran (35 ml.) is added dropwise followed by triethylamine (3.22 ml., 23 mmole).Additional triethylamine is added to maintain a basic atmosphere. After 20 minutes the ice-bath is removed and the reaction mixture is kept at room temperature overnight. The triethylamine hydrochloride is filtered off and the filtrate is concentrated to dryness in vacuo. The residue is taken into pyridine (25 ml.) and 4-dimethylamino pyridine (75 mg.) is added and the solution is stirred for 3 hours under an argon atmosphere. Acetic acid (25 ml.) is added and the reaction mixture is stirred for 45 minutes at 100 under a positive flow of argon. The reaction mixture is concentrated to dryness, taken into ethyl acetate, and washed neutral with saturated sodium bicarbonate and dilute hydrochloric acid.The crude product (12.8 g.) is chromatographed on silica gel eluting with ethyl acetate:hexane (1:1) to give 9.05 g. of (+)-1-[N-[N-[3- (benzoylamino)-2-oxo-4-phenylbutyl]-N-[(phenylmethoxy)carbonyl]-L-alanyl]-L-proline,1,1-dimethylethyl ester.
d) ()-1-[N-[N-[3-(Benzoylamino)-2-oxo-4-phenylbutyl]-N-[(phenylmethoxy)carbonyl]-L-alanyl]-L-proline The ester product from part (c) (11.4 g., 17.7 mmole) is taken into trifluoroacetic acid (50 ml.) and kept at room temperature for 45 minutes. It is then concentrated to dryness and triturated with ether:hexane to yield 10.3 g. of crude product. This material is purified on a silica gel column in benzene/acetic acid (8:2) to give 9.7 g. of ()-1-[N-[N-[3-(benzoylamino)-2-oxo-4-phenylbutyl]-N-[(phenylmethoxy)carbonyl]-L-alanyl]-L-proline; m.p.70- 91 ; [a]2D3 = -53.0 (c = 1.22, methanol). Rf 0.41 (silica gel, benzene/aceticacid; 8:2).
Anal. calc'd. for C33H35N307 C,67.68; H,6.02; N,7.17 Found: C,67.95; H, 6.02; N,6.82.
e) ()-1-[N-[N-[3-(Benzoylamino)-2-oxo-4-phenylbutyl]-N-[(phenylmethoxy)carbonyl]-L-alanyl]-L-proline, methyl ester The acid product from part (d) (3.5 g., 6 mmole) is taken into dimethylformamide (12 ml.) with stirring at room temperature. To this sodium bicarbonate (630 mg., 7.5 mmole) and methyl iodide (0.47 ml., 7.5 mmole) are added. After 18 hours, additional methyl iodide (7.4 mmole) and sodium bicarbonate (7.4 mmole) are added. After 18 hours, additional methyl iodide (7.4 mmole) and sodium bicarbonate (7.4 mmole) are added.
After stirring for an additional 4 hours, the reaction mixture is concentrated to dryness in vacuo, taken into ethyl acetate and washed with saturated sodium bicarbonate. The crude product (3.7 g.) is purified on a silica gel column in ethyl acetate:hexane (2;1) to give 3.5 g. of (r)-l-[N-[N-[3-(benzoyiamino)-2-oxo-4- phenylbutyl]-N-[(phenylmethoxy)carbonyl]-L-alanyl]-L-proline, methyl ester.
f) ()-1-[N-[3-(benzoylamino)-2-oxo-4-phenylbutyl]-L-alanyl]-L-proline, methyl ester, m onoh ydrochloride The ester product from (e) (900 mg., 1.5 mmole) is taken into ethanol (95%, 100 ml.) and 1 N hydrochloric acid (1.8 ml.). Palladium on carbon catalyst (10%, 180 mg.) is added and the reaction mixture is stirred under hydrogen overnight. The reaction mixture is filtered to remove the catalyst, concentrated to dryness and lyophilized twice from water to give 700 mg. of (+)-1 -[N-[3-(benzoylamino)-2-oxo-4-phenylbutyl]-L-alanyl]-L- proline, methyl ester, monohydrochloride; m.p. 110-128'(90'); [a)023 [&alpha;]D23 = -69.9 (c = 1.18, methanol). Rf 0.63 (silica gel, chloroform/methanol/acetic acid; 9:1:1).
Anal. calc'd. for C26H31N305 . HCl . 0.92 H2O: C, 60.22; H, 6.58; N, 8.11; Cl, 6.84 Found: C,60.22; H,6.28; N,8.10; Cl,7.06.
EXAMPLE 110 ()-1-[N-[3-(Benzoylamino)-2-oxo-4-phenylbutyl]-L-alanyl]-L-proline, methyl ester, monomethanesulfonate (+)-1 -[N-[N-[3-(Benzoylamino)-2-oxo-4-phenylbutyl]-N-[(phenylmethoxy)carbonyl]-L-alanylj-L-proline, methyl ester (600 mg., 1 mmole), prepared as set forth in Example 109 (e), is taken into methanol (60 ml.) and methanesulfonic acid (0.066 ml., 1 mmole). Palladium on carbon catalyst (10%, 120 mg.) is added and the reaction mixture is stirred under hydrogen for 2.5 hours. The reaction mixture is filtered to remove the catalyst and then concentrated in vacuo. The crude product is triturated with ether and filtered. The precipitate is taken into water and lyophilized to yield 470 mg. of (~)-1 -[N-[3-(benzoylamino)-2-oxo-4 phenylbutyl]-L-alanyl]-L-proline, methyl ester, monomethanesulfonate; rA.p. 80-140'; [a]D3 = -61.4 (c = 1.10, methanol). Rf 0.63 (silica gel, chloroform/methanol/acetic acid; 9:1:1).
Anal. calc'd. for C26H31N3O5 . CH4O3S C,56.98; H, 6.34; N,7.30; S,5.63 Found: C, 56.98; H, 6.32; N, 7.47; S, 5.63.
EXAMPLE 111 ()-1-[N-[3-(Benzoylamino)-2-oxo-4-phenylbutyl]-L-alanyl]-L-proline, methyl ester, hemisulfate (+)-1 -[N-[N-[3-(Benzoylamino)-2-oXo-4-phenylbutyl]-N-[(phenylmethoxy)carbonyl]-L-aianyl]-L-proline, methyl ester (600 mg., 1 mmole), prepared as set forth in Example 109 (e), is taken into methanol (40 ml.) along with 1N sulfuric acid (0.9 ml.). Palladium on carbon catalyst (10%, 120 mg.) is added and the reaction mixture is stirred under hydrogen for 2 hours. The reaction mixture is filtered to remove the catalyst, concentrated to dryness, triturated with ether and filtered.The crude product (446 mg.) is taken into water, millipore filtered, and lyophilized to yield 405 mg. of (+)-1-[N-[3-(benzoylamino)-2-oxo-4-phenylbutyl]-L- alanyl]-L-proline, methyl ester, hemisulfate; m.p. 98 - 112 (85 ); [a]203 = -60.3 (c = 1.16, methanol). Rf 0.63 (trailing) (silica gel, chloroform/methanol/acetic acid; 9:1:1).
Anal. calc'd. for C26H31N305 0.5 H2SO4 0.91H2O: C,58.81; H,6.42; N,7.92; S,3.01 Found: C,58.81; H, 6.11; N,7.91; S,3.09.
EXAMPLE 112 ()-1-[N-[3-(Benzoylamino)-2-oxo-4-phenylbutyl]-L-alanyl]-L-proline, propyl ester, monomethanesulfonate a) ()-1-[N-[N-[3-(Benzoylamino)-2-oxo-4-phenylbutyl]-N-[(phenymethoxy)carbonyl]-L-alanyl]-L-proline, propyl ester ()-1-[N-[N-[3-(Benzoylamino)-2-oxo-4-phenylbutyl]-N-[(phenylmethoxy)carbonyl]-L-alanyl]-L-proline (1.17 g., 2 mmole), prepared as set forth in Example 109 (d), is taken into tetrahydrofuran (2 ml.) with stirring in an ice-bath. To this is added n-propanol (3.0 ml., 40 mmole) followed by 4-dimethylamino pyridine (122 mg., 1 mmole) and dicyclohexylcarbodiimide (412 mg., 2 mmole). The reaction is allowed to warm to room temperature and to run overnight. The dicyclohexylurea is filtered off and the filtrate is concentrated to dryness in vacuo.The crude product (1.2 g.) is chromatographed on a silica gel column in benzene:acetic acid (9:l)to yield 1.0 g. of()-l-[N-[N-[3-( benzoylamino)-2-oxo-4-phenyl butyl]-N-[(phenyl methoxy) car- bonyl]-L-alanyl]-L-proline, propyl ester.
b) ()-1-[N-[3-)Benzoylamino)-2-oxo-4-phenylbutyl]-L-alanyl]-L-proline, prop yl ester monomethanesulfonate The ester product from part (a) (500 mg., 0.8 mmole) is taken into methanol (50 ml.). Methanesulfonic acid (0.72 ml. of 1N solution in methanol) and palladium on carbon catalyst (10%,100 mg.) are added and the reaction mixture is stirred under hydrogen overnight. The reaction mixture is filtered to remove the catalyst, concentrated to dryness, triturated with ether and filtered to yield 406 mg. of crude product.This is taken into water, millipore filtered, and lyophilized to yield 390 mg. of ()-1-[N-[3-(benzoylamino)-2-oxo-4- phenylbutyl]-L-alanyl]-L-proline, propyl ester, monomethanesulfonate; m.p. 82-94 (69 ); [a]23 = -60.5 (c = 0.95, methanol). Rf0.46 (silica gel, chloroform/methanol/acetic acid; 90:5:5).
Anal. calc'd. fOTC28H35N305 . CH4O3S 0.5 H20: C,58.15; H,6.73; N,7.01; S,5.34 Found: C, 58.15; H, 6.63; N, 7.05; S, 5.34.
EXAMPLE 113 ()1-[N-[3-(Benzoylamino)-2-oxo-4-phenylbutyl]-L-alanyl]-L-proline, ethyl ester, monomethanesulfate a) (t)- 1-[N-[N-[3-(Benzoylamino)-2-oxo-4-phenylbutyl]-N-[(phenylmethoxy)carbonyl]-L-alanyl]-L-proline, ethyl ester ()-1-[N-[N-[3-(Benzoylamino)-2-oxo-4-phenylbutyl]-N-[phenylmethoxy)carbonyl]-L-alanyl]-L-proline (1.17 g., 2 mmole), prepared as set forth in Example 109 (d), is taken into tetrahydrofuran (2 ml.) with stirring in an ice-bath. To this is added absolute ethanol (2.3 ml., 40 mmole) followed by 4- dimethylamino pyridine (122 mg., 1 mmole) and dicyclohexylcarbodiimide (412 mg., 2 mmole). The reaction is allowed to run overnight at room temperature.The dicyclohexylurea is filtered off, the filtrate is concentrated to dryness, the residue is taken into ethyl acetate and washed neutral with 10% potassium bisulfate and saturated sodium carbonate. The crude product (1.2 g.) is purified on silica gel column in benzene; acetic acid (8:2) to yield 1.0 g. of ()-1-[N-[N-[3-(benzoylamino)-2-oxo-4-phenylbutyl]-N-[(phenylmethoxy)carbonyl]-L-alanyl]-L- proline, ethyl ester.
b)()-1-[N-[3-(Benzoylamino)-2-oxo-4-phenylbutyl]-L-alanyl]-L-proline, ethyl ester, monomethanesulfate The ester product form part (a) (500 mg., 0.8147 mmole) is taken into 50 ml. of methanolmethanolic methanesulfonic acid (1N, 0.733 ml.). Palladium on carbon catalyst (10%, 100 mg.) is added and the reaction mixture is stirred under positive hydrogen pressure for 3 hours. The reaction mixture is filtered to remove the catalyst, concentrated to dryness, triturated with ether and filtered.The precipitate (428 mg.) is taken into water, millipore filtered, and lyophilized to yield 360 mg. of (a)-l-[N-[3-(benzoylamino)-2-oxo-4- phenylbutyl]-L-alanyl]-L-proline, ethyl ester, monomethanesulfonate; m.p. 91 - 96 (72 ); [a)23 - -57.2" (c = 1.04, methanol). Rf 0.44 (silica gel, chloroform/methanol/acetic acid; 90:5:5).
Anal.calc'd.for C27H33N3O5 . CH4S03 0.6 H2O: C, 57.33; H, 6.56; N, 7.17; S, 5.47 Found: C, 57.33; H, 6.43; N, 7.12; S, 5.47.
EXAMPLE 114 ()-1-[N-[3-(Benzoylamino)-2-oxo-4-phenylbutyl]-L-alanyl]-L-proline, 1-methylethyl ester, monomethanesulfonate a) ()-1-[N-[N-[3-(Benzoylamino)-2-oxo-4-phenylbutyl]-N-[(phenylmethoxy)carbonyl]-L-alanyl]-L-proline, 1 methylethyl ester (i)-1 -[N-[N-[3-(Benzoylamino)-2-oxo-4-phenylbutyl]-N-[(phenylmethoxy)carbonyl)-L-alanyl]-L-proline (1.17 g., 2 mmole), prepared as set forth in Example 109 (d), and isopropanol (3.0 ml., 40 mmole) are taken into tetrahydrofuran (2 ml.) with stirring in an ice-bath. To this dicyclohexylcarbodiimide (412 mg., 2 mmole) is added. The reaction is allowed to run overnight at room temperature. It is then concentrated to dryness, taken into ethyl acetate and the dicyclohexylurea filtered off.The filtrate is washed neutral with 10% potassium bisulfate and saturated sodium bicarbonate. The crude product (1.2 g.) is purified on a silica gel column with benzene:acetic acid (8:2) to yield 1.0 g. of ()-1-[N-[N-[3-(benzoylamino)-2-oxo-4-phenylbutyl]- N-[(phenylmethoxy)-carbonyl]-L-alanyl]-L-proline,1-methylethyl ester.
b) ()-1-[N-[3-(Benzoylamino)-2-oxo-4-phenylbutyl]-L-alanyl]-L-proline, 1-methylethyl ester, monomethanesulfonate The ester product from part (a) (815 mg., 1.3 mmole) is take into methanol (20-ml.) and methanolic methanesulfonic acid (iN, 1.17 ml.) and stirred under hydrogen in the pressence of palladium on carbon catalyst (10%,160 mg.) for 3 hours. The reaction mixture is filtered to remove the catalyst and concentrated to dryness in vacuo. The residue is triturated with ether and the precipitate filtered to yield 704 mg. of crude product.This is taken into 35 ml. of water (2% solution), millipore filtered, and lyophilized to give 600 mg. of ()-1-[N-[3-(benzoylamino)-2-oxo-4-phenylbutyl]-L-alanyl]-L-proline,1-methylethyl ester, monomethanesul fonate; m.p. 88-105'; [a)203 = -55.2" (c = 1.05, methanol). Rf 0.33 (silica gel, chloroform/methanol/acetic acid; 9:1:1).
Anal.calc'd.for C28H35N3O5 CH4O3S 0.66 H2O: C, 57.89; H, 6.75; N, 6.99; S, 5.33 Found: C, 57.89; H, 6.62; N, 6.62; S, 5.32.
EXAMPLES 115-123 Following the procedure of Examples 109, 112, 113 and 114, ()-1-[N-[-3-(benzoylamino)-2-oxo-4- phenylbutyl]-N-[(phenylmethoxy)carbonyl]-L-alanyl]-L-proline is treated with the reagent shown below in Col. i. Removal of the alanyl protecting group yields the ester product shown below in Col. IL Col. II
t,xamplis Cal. t A6 o o II I' 115 Cl-CR-C-. CC 2R5 -CK-O-C-C b O o o I II 116 Cl-CN-O-C-C2H5 -CH-O-C-CZHS CH 1CH3) 2 CH (CN3) 2 32 32 O 0 II b 117 Cl-CH2-O-C-CtCH3) 3 -CH2 -O-C-C (CH3 ) 3 O 0 II II 118 Br- CH1-O-C-CH3 -o-c-cH O 0 119 Cl-CR2-0-C11 CR2cch O O II II 120 I-CH2-C-O-C (CH3 ) 3 -CH -C-O-C (CH ) CR3 O CR3 O 1 3 Ii 1 3 121 T-C- C-O-CH3 C - C-O-CH3 CH3 CH3 1. 122 CH- (CH2-O-CH2 4 ) 2 -CR (CH2- H) 2 2 OR 123 CM1 CUB H2 -CH2-CHCH2 I II OH O O OH 1 I R2C
EXAMPLE 124 1-[N-[(S)-3-(Benzoylamino)-2-oxo-4-phenylbutyl]-L-alanyl]-L-proline, sodium salt 1-[N-[(S)-3-(Benzoylamino)-2-oxo-4-phenylbutyl]-L-alanyl]-L-proline, hydrochloride (424 mg., 1 mmole) is dissolved in water (50 ml.). Aqueous sodium bicarbonate (0.1 N, 20 ml.) is added and the aqueous solution is lyophilized. It is then dissolved in water (10 ml.) and applied on a column (5 cm. x 60 cm.) of Sephadex chromatography gel G-10 and eluted with water. Fractions containing the desired product are pooled and lyophilized to obtain 1-[N-[(S)-3-(benzoylamino)-2-oxo-4-phenylbutyl]-L-alanyl]-L-proline, sodium salt.
EXAMPLE 125 1000 tablets each containing the following ingredients l-[N-[(S)-3-(Benzoyl- amino)-2-oxo-4-phenyl- butyl]-L-alanyl]-L- proline, sodium salt 100 mg.
Corn starch 50 rng.
Gelatin 7.5 mg.
Avicel (microcrystalline cellulose) 25 mg.
Magnesium stearate 2.5 mg.
are prepared from sufficient bulk quantities by mixing the 1-[N-[(s)-3-tbenzoylamino)-2-oxo-4-phenylbutyll- L-alanyl]-L-proline, sodium salt and corn starch with an aqueous solution of the gelatin. The mixture is dried and ground to a fine powder. The Avicel and then the magnesium stearate are admixed with granulation.
This mixture is then compressed in a tablet press to form 1000 tablets each containing 100 mg. of active ingredient.
In a similar manner, tablets containing 100 mg. of the product of any of Examples 1 to 123 can be prepared.
A similar procedure can be employed to form tablets containing 50 mg. of active ingredient.
EXAMPLE 126 Two piece *1 gelatin capsules each containing 50 mg. of 1-[N-[(S)-3-(benzoylamino)-2-oxo-4-phenylbutyl]- L-alanyl]-L-proline, sodium salt are filled with a mixture of the following ingredients: l-[N-[(S)-3-(Benzoylamino) 2-oxo-4-phenylbutyl]-L alanyl] -L-proline, sodium salt 50 . mg.
Magnesium stearate 7 mg.
Lactose 193 mg.
250 mg.
In a similar manner capsules containing 50 mg. of the product of any of Examples 1 to 123 can be prepared.
EXAMPLE 127 An injectable solution is prepared as follows: l-[N-[(S)-3-(Benzoyl amino) - 2-oxo- 4-phenyl butyll -L-alanyl] -L- proline, sodium salt 500 g.
Methyl paraben 5 g.
Propyl paraben 1 g.
Sodium chloride 25 g.
Water for injection 5 1.
The active substance, preservatives, and sodium chloride are dissolved in 3 liters of water for injection and then the volume is brought up to 5 liters. The solution is filtered through a sterile filter and aseptically filled into presterilized vials which are closed with presterilized rubber closures. Each vial contains 5 ml. of solution in a concentration of 100 mg. of active ingredient per ml. of solution for injection.
In a similar manner, an injectable solution containing 100 mg. of active ingredient per ml. of solution can be prepared for the product of any Examples 1 to 123.
EXAMPLE 128 1000 tables each containing the following ingredients: 1- [N- ((5) -3- (Benzoyl- amino) -2-oxo-4-phenyl- butyl]-L-alanyl]-L- proline, sodium salt 100 mg.
Avicel 100 mg.
Hydrochlorothiazide 12.5 mg.
Lactose 113 mg.
Cornstarch 17.5 mg.
Stearic acid 7 mg.
350 mg.
are prepared from sufficient bulk quantities by slugging the l-[N-[(S)-3-(benzoylamino)-2-oxo-4- phenylbutyl]-L-alanyl]-L-proline, sodium salt, Avicel, and a portion of the stearic acid. The slugs are ground and passed through a #2 screen, then mixed with the hydrochlorothiazide, lactose, cornstarch, and remainder of the stearic acid. The mixture is compressed into 350 mg. capsule shaped tablets in a tablet press. The tablets are scored for dividing in half.
In a similar manner, tablets can be prepared containing 100 mg. of the product of any of Examples 1 to 123.

Claims (3)

1. Acompound oftheformula
wherein halo is Cl or Br; R2is
R3 is hydrogen, lower alkyl,
halo substituted lower alkyl, (CH2)m-cycloalkyl,
-(CH2)r-NH2, -(CH2)r-SH, -(CH2)r-S-lower alkyl,
R14 is hydrogen, lower alkyl of 1 to 4 carbons, lower alkoxy of 1 to 4 carbons, lower alkylthio of 1 to 4 carbons, chloro, bromo, fluoro, trifluoromethyl, or hydroxy; m is zero, one, two, three, or four; p is one, two or three provided that p is more than one only if R14 is hydrogen, methyl, methoxy, chloro, or fluoro; and r is an integerfrom 1 to 4.
2. A compound according to Claim 1 wherein R2 is
R3is
m is zero, one, or two; and R14 is hydrogen, methyl, methoxy, methylthio, chloro, bromo, fluoro, or hydroxy.
3. A compound according to Claim 2, wherein R2 is
R3 is
and halo is Cl.
GB08505628A 1982-07-19 1985-03-05 Substituted peptide compounds Withdrawn GB2155470A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB08505628A GB2155470A (en) 1982-07-19 1985-03-05 Substituted peptide compounds

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39965082A 1982-07-19 1982-07-19
GB08505628A GB2155470A (en) 1982-07-19 1985-03-05 Substituted peptide compounds

Publications (3)

Publication Number Publication Date
GB2155470B GB2155470B (en)
GB8505628D0 GB8505628D0 (en) 1985-04-03
GB2155470A true GB2155470A (en) 1985-09-25

Family

ID=26288910

Family Applications (1)

Application Number Title Priority Date Filing Date
GB08505628A Withdrawn GB2155470A (en) 1982-07-19 1985-03-05 Substituted peptide compounds

Country Status (1)

Country Link
GB (1) GB2155470A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0127124A2 (en) * 1983-05-23 1984-12-05 Usv Pharmaceutical Corporation Compounds for treating hypertension
FR2639946A1 (en) * 1988-12-07 1990-06-08 Tanabe Seiyaku Co PEPTIDES CONTAINING IMIDAZOLE, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JP 77/99380 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0127124A2 (en) * 1983-05-23 1984-12-05 Usv Pharmaceutical Corporation Compounds for treating hypertension
EP0127124A3 (en) * 1983-05-23 1987-04-08 Usv Pharmaceutical Corporation Compounds for treating hypertension
FR2639946A1 (en) * 1988-12-07 1990-06-08 Tanabe Seiyaku Co PEPTIDES CONTAINING IMIDAZOLE, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
EP0372818A2 (en) * 1988-12-07 1990-06-13 Tanabe Seiyaku Co., Ltd. Imidazole-containing peptide and preparation thereof
EP0372818A3 (en) * 1988-12-07 1991-05-15 Tanabe Seiyaku Co., Ltd. Imidazole-containing peptide and preparation thereof
AU620666B2 (en) * 1988-12-07 1992-02-20 Tanabe Seiyaku Co., Ltd. Imidazole-containing peptide and preparation thereof
US5202312A (en) * 1988-12-07 1993-04-13 Tanabe Seiyaku Co., Ltd. Imidazole-containing peptides having immunomodulatory activity

Also Published As

Publication number Publication date
GB2155470B (en)
GB8505628D0 (en) 1985-04-03

Similar Documents

Publication Publication Date Title
EP0132304B1 (en) Hydroxy substituted peptide compounds
USH725H (en) Ureido amino and imino acids, compositions and methods for use
EP0052991B1 (en) Carboxyalkyl amino acid derivatives of various substituted prolines
US4826815A (en) Renin inhibiting compounds
EP0223437A2 (en) Aminocarbonyl renin inhibitors
EP0216539A2 (en) Novel amino acid derivatives
EP0303434A1 (en) Thiazolidine compounds
GB2130221A (en) Carboxy and substituted carboxy alkanoyl and cycloalkanoyl peptides
EP0142335A2 (en) Lactam containing compounds
CA1261332A (en) Ester substituted aminoalkanoylureido amino and imino acid and ester compounds
CA1269496A (en) Mercaptocycloalkylcarbonyl and mercaptoarylcarbonyl dipeptides
EP0159156A1 (en) Hydroxy substituted ureido amino and imino acids
US4711884A (en) Thiazine and thiazepine containing compounds
EP0103496A1 (en) Acylalkylaminocarbonyl substituted amino and imino acid compounds
CA1244006A (en) Substituted peptide compounds
EP0158947B1 (en) Amino thiol dipeptides
US5643879A (en) Amino-substituted heterocycles as renin inhibitors
US4568489A (en) N-Acyl-γ-glutamyl imino and amino acids and esters
GB2155470A (en) Substituted peptide compounds
US5219851A (en) Tetrahydroisoquinoline-type renin inhibiting peptides
US4692455A (en) Certain acyclic, alicyclic, aromatic or heterocyclic derivatives of 3-benzoylamino-2-oxo- butyl-amino-carbonyl-oxy-3-propanoic acids, esters thereof, pharmaceutical compositions containing same and their enkephalinase inhibiting properties
GB2155924A (en) Substituted peptide compounds
CA1285563C (en) Ureidoalkanoylaminocarbonyl amino and imino acids and esters
US5149692A (en) Bisalkoxyphosphinyl compounds as renin inhibitors
WO1989010751A1 (en) Functionalized peptidyl aminodiols and -triols

Legal Events

Date Code Title Description
PCNP Patent ceased through non-payment of renewal fee

Effective date: 19930708